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ABSTRACT 
 
The complex and vulnerable tissue of the spinal cord does not heal after injury, leaving patients with 
lifelong disability after spinal cord injury (SCI). Many milestones have been reached during the last 
century through specialized centers for SCI, greatly increasing life expectancy and quality of life by 
battling common medical problems such as urinary tract infections, pressure ulcers, spasticity, 
neurogenic pain, and sexual function as well as providing means of rehabilitation to a meaningful 
and productive life after SCI. Despite the advances in preclinical knowledge of mechanisms in SCI 
and several clinical trials completed, to date no pivotal treatment exists for acute spinal cord injury or 
for the regeneration of lost function in the chronic state. The first reports of experimental 
regeneration of central axons through peripheral nerve grafts are more than a century old. In the last 
decades, regeneration of function after SCI has been reported by several research groups in different 
species using peripheral nerve grafts and FGF1. The regeneration strategy was furthered refined in 
our group by the use of a biodegradable scaffold for exact positioning of the nerve grafts. This thesis 
describes the translational process to reach a clinical trial of glial scar resection and implantation of 
peripheral nerve grafts and FGF1 using a biodegradable guiding scaffold. 
In paper I, we show that both the cranial and caudal demarcation of a thoracic spinal cord 
injury can be defined with electromyography of intercostal muscles in chronic SCI patients. We also 
present an MRI protocol with acceptable image contrast despite the presence of spinal 
instrumentation and showed that the injury length found with electromyography correlates well 
with length of injury on MRI. 
In paper II, we use a novel conversion table between spinal cord neuronal segments and 
vertebral segments and combine data on human spinal cord cross-sectional diameters from different 
published sources to yield continuous estimates on human spinal cord size and variability. 
In paper III, we describe the design of a set of spinal cord injury guiding devices based on the 
data from paper II, covering the normal variability found in human thoracic spinal cord segments 
T2–T12 with an acceptable error-of-fit for the elliptical shape as well as guiding channels proposed. 
In paper IV, we detail the adverse events reported during the first 60 days postoperatively in 
the ongoing clinical trial “Safety and Efficacy of SC0806 (Fibroblast Growth Factor 1 and a Device) 
in Traumatic Spinal Cord Injury Subjects.” Early results from the first six complete (AIS-A) thoracic 
spinal cord injury subjects operated on in the ongoing trial show that with precise preoperative and 
intraoperative neurophysiology, surgery and implantation can be performed without negative effects 
on neurological level, and safety and tolerability are acceptable to merit the continuation of the trial. 
In paper V, we describe the construction of a cost-effective light-sheet microscope by 
modification of an outdated microarray-scanner. The microscope was applied to an experimental 
model of hypoglossal nerve avulsion injury, and proliferation of Iba1+ cells could be quantified 
automatically demonstrating a possible application of the microscope. 
 
In conclusion, reaching clinical trial in a translational process is a significant and collaborative 
undertaking requiring co-operation of multiple institutions and professions as well as rigorous 
external control of data quality and adverse events to ensure safety of study subjects. The papers in 
this thesis detail some relevant steps necessary for the clinical translation of regeneration strategies in 
chronic SCI. 
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THE SPINAL CORD AND MICROSCOPIC INVESTIGATION 
THE SPINAL CORD IS AN EXTENSION OF THE BRAIN 
The spinal cord in humans is a thin structure that extends from the base of the skull via the neck to 
halfway through the torso. The spinal cord resides inside the spinal canal of the spinal vertebrae. The 
spinal cord contains most of the connections between the brain and the body, such as the conscious 
instruction to perform a voluntary movement of a finger to touch an object and the sensory 
information from the fingertip telling the brain of the tactile properties of the object (1). 
However, the spinal cord is not just a cable between the brain and the body. It also contains 
many important modulations of the information passed to and from the brain. Motor neurons in 
the spinal cord take input from the brain, amplify the electrical signal, and directly activate muscles. 
The sensory neurons of the dorsal ganglia (situated outside spinal cord) modulate and pass 
information to the brainstem via the spinal cord but also connect directly to other neurons of the 
spinal cord. 
The spinal cord can even perform tasks entirely on its own such as the extensor reflex (the jerk 
of the leg that medical doctors examine with a reflex hammer). This activation of motor neurons and 
subsequent movement of a muscle is performed entirely without input from the brain. Even vastly 
more complicated tasks such as walking and micturition have been shown to rely in part on spinal 
cord circuitry, with the brain only providing modulation to activate these spinal pattern generators 
in a purposeful manner (1,2). 
As a whole, the spinal cord can be thought of as an extension of the brain, with its own 
connections, neurons, and autonomous circuitry. This is reflected in the term “central nervous 
system” (CNS), which entails the brain, the brainstem, and the spinal cord. 
THE BODY IS REPRESENTED IN SPECIFIC SEGMENTS OF THE CORD 
The inflow to and outflow from the spinal cord are continuous along the craniocaudal axis (“from 
head to tail”) through dorsal (toward the back) and ventral (toward the front) rootlets. The spinal 
cord can be anatomically divided into segments depending on how these rootlets gather in bundles 
termed ventral and dorsal roots. The ventral and dorsal roots gather in spinal nerves when they exit 
the spinal canal.  
Outside the spinal canal, the spinal nerves form peripheral nerves or exchange fiber bundles 
with other spinal nerves in plexae and then form peripheral nerves. The peripheral nerves form 
connections with muscles and skin in the body and function as cables between the central nervous 
system and the target organ. Autonomic (non-voluntary) fibers also exit the CNS through the spinal 
nerves and connect with plexae of the autonomic nervous system, which involves modulation of 
blood pressure, heart rate, and sweating, among other functions. 
The neuronal function of a certain part of the human body is closely correlated to certain 
segments in the spinal cord, with almost no variation between individuals. Simplified, the arms 
belong to the cervical spinal cord, the trunk to the thoracic spinal cord, the legs to the lumbar spinal 
cord, and the anogenital tract to the sacral spinal cord. Because of the anatomy of the spinal cord, a 
complete injury to the cord at a certain level leads to complete loss of sensory and voluntary motor 
function below the level of injury.  
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THE SPINAL CORD IS COMPOSED OF CELL BODIES AND AXONS 
The spinal cord tissue is classically subdivided between white and grey matter. White matter is 
composed of longitudinal axonal connections traversing many segments, often between cortex and 
spinal cord (corticospinal tracts), brainstem and spinal cord (e.g. rubrospinal tract), or spinal cord 
and spinal cord (propriospinal tracts). Grey matter contains neuronal cell bodies and shorter axons 
within the same segment or between adjacent segments (1). 
Grey matter can be further subdivided in the lamina of Rexed (1), a classification based on how 
the cells encountered in the different parts of the grey matter appear in the microscope. Later 
examination with single-cell transcriptomics (where a more precise identity of the cells are 
determined by analyzing which genes the cells use) supports the view of a functional laminar 
organization of the spinal cord grey matter (3,4). 
White matter can be classified according to the function of the axonal connection in a specific 
anatomical location. In animal experiments, the exact location of spinal tracts is well-characterized 
through the use of neuroanatomical tracers that enable isolation of a specific tract or even single axons 
(1,5,6). In humans, however, knowledge of the anatomical location of the white matter tracts of the 
spinal cord is based on careful postmortem dissection, case reports of clinical findings from precisely 
defined injuries, and post-mortem microscopic examination of patients who suffered cerebral 
infarction weeks to months before dying of other causes. By observing signs of degeneration of white 
matter tracts in the spinal cord of these patients, the anatomical location of the projections from the 
brain to the spinal cord has been deduced (7). Many axons in both white and grey matter are 
surrounded by myelin sheets electrically insulating the axon more efficiently than cell membranes 
and enabling faster conduction of the axon potentials, the principal long-distance data-transmission 
mode in the nervous system (8). 
AXONS ARE EXCEPTIONALLY LONG AND THIN 
The axonal processes of neurons are exceptionally thin and long. An axon of a couple of micrometers 
can be one meter long and thus have a width-to-length ratio of 1:200,000. That ratio is comparable 
to the width of a driving lane from Stockholm to Berlin. An important reason for the lack of 
knowledge of the exact axonal projections and spinal cord circuitry in humans is that classical wide-
field microscopy requires the tissue to be mechanically cut in thin sections. Because of artifacts 
between sections, reconstruction of intact circuitry has been impossible. A second problem with thin 
sections is quantification of cell numbers in a tissue volume. This has been solved in the past by 
various statistical approaches such as manually counting all cells on a defined number of thin sections 
(9), but the technique has been prohibitively time-consuming for many applications. 
OPTICAL SECTIONS PRESERVE THREE-DIMENSIONAL STRUCTURE 
Confocal microscopy allows separation of image planes through the optics of the microscope by 
rejection of out-of-focus light with a pinhole. With optical sectioning, it is possible to image axonal 
process and cells in much thicker sections than with conventional wide-field microscopy. 
Unfortunately, mechanical sections are still needed because biological tissue is an inhomogeneous 
optical medium for visible wavelengths of light resulting in refraction between, for example, 
extracellular fluid and cell membranes and proteins (10). After passing just half a millimeter through 
tissue, statistically most photons have changed direction in an uncontrolled fashion at least one time, 
and extracting high-resolution information is impossible. The effect is similar to shining a flashlight 
through a finger: the light passes through, but internal structures cannot be visualized because of 
scattering (10). 
OPTICAL SECTIONING
EXCITATION
DETECTION
Refractive index
matching of tissue
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TISSUE CAN BE MADE TRANSPARENT BY REFRACTIVE INDEX MATCHING 
During the last decade, several methods for homogenizing a refractive index of biological tissue 
without disrupting structural organization of the tissue on a microscopic and molecular level have 
been published (11–14). The tissue becomes virtually transparent, and by using microscopic 
techniques for optical sectioning such as confocal microscopy, questions such as the true course of 
an axon in the nervous system can be tackled. 
The possibility of imaging deep in biological tissue has given rise to a new set of problems. For 
example, microscopic objectives are commonly made for short working distance between the front 
lens and the object, creating a physical barrier for imaging deep into transparent tissue. Theoretically, 
longer working-distance objectives can be built from the exact same design as short working-distance 
objectives, but scaling up sizes of the glass surfaces greatly increases cost. Second, confocal microscopy 
records data one voxel at a time, making imaging of three-dimensional volumes impractical because 
image acquisition time becomes too long. Confocal microscopy also rejects the majority of 
fluorescence exited, leading to photobleaching in adjacent Z-planes and deterioration of image 
contrast when fluorescence is used to create image contrast. 
LIGHT-SHEET MICROSCOPY IS IDEAL FOR IMAGING TRANSPARENT TISSUE 
Some of the limitations with confocal microscopy for imaging of large volumes of tissue have been 
overcome by achieving optical sectioning with structured illumination from a second objective 
situated perpendicular to the detection objective instead of a pinhole. In this setup, wide-field 
detection can be used, and the image can be captured on a camera sensor (typically millions of voxels 
per exposure instead of one as in confocal microscopy). Additionally, because only in-focus 
fluorophores are excited, none of the emitted fluorescence needs to be rejected, leading to reduced 
photobleaching compared to confocal microscopy (15). 
The development of light-sheet microscopes has been rapid in the last decade, with many 
significant improvements and applications such as multiple light-sheets and detection (16), contrast-
enhancing strategies (17), two-photon excitation (18), automatic focusing with adaptive optics 
(19,20), Bessel-beam illumination (21), transient state imaging (22), super-resolution using stimulated 
emission depletion (23), or lattice light-sheets (24). Despite the potential of light-sheet microscopy, 
commercial products are sparse. With low volumes and high prices, they represent a significant 
investment for most research groups. The different custom light-sheet microscopy setups published 
are usually aimed at answering different specific questions; therefore, most of the published setups 
are not directly comparable. Each has its advantage and disadvantage, and the diversity in 
specifications is significant (25). 
Light-sheet microscopy has the potential to gather the information available by making 
biological tissue transparent and the potential to transform understanding of three-dimensional 
anatomy of, for example, axonal projections and distributions of specific cell types in normal spinal 
cord physiology and spinal cord injury. However, for startup projects, the cost of purchasing a 
commercial light-sheet microscope or establishing a custom instrument is a major barrier to 
application. An initiative termed “Open-SPIM” has made a significant effort to describe in detail the 
construction of a cost-effective setup based on commercial optical components (26). However, the 
price for constructing an Open-SPIM is still around USD 60,000 (27). 
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INJURY TO THE SPINAL CORD 
THE CENTRAL NERVOUS SYSTEM IS SOFT AND FRAGILE 
The central nervous system (CNS) is exceptionally soft compared to other tissues in the body. The 
CNS is “floating” in the cerebrospinal fluid (CSF), and the structural integrity of the CNS is actually 
so low that it will deform under its own weight when not suspended in water, much like a stranded 
jellyfish. The CNS is not only soft, but it is also exceptionally vulnerable. Unlike other soft tissues of 
the body, the CNS does not tolerate fast deformation. On short timescales, the tight-woven complex 
structure of axons, cell membranes, and small blood vessels in the nervous system behaves almost like 
glass. The internal structures of the CNS will “shatter” with a surprisingly small deformation. One 
important reason for this property of the nervous system is the densely packed axons, as showed by 
recent advances in computer modeling of CNS tissue (28). When deformation of the CNS is slow 
(e.g. with slow-growing tumors), a remarkable deformation can occur without clinical symptoms. 
Some authors even propose the elastic modulus of the CNS in this setting to be zero—that is, the 
CNS is a liquid on long timescales (29–31), just like cats (32). 
In a pig model of spinal cord injury (SCI) that resembles human dimensions, a 20-gram weight 
dropped from a height of 25 cm onto the exposed spinal cord was enough to induce a spinal cord 
injury (33). The force used in the study is equivalent to dropping the blunt end of a reservoir pen 
from your raised hand onto the desk in front of you. Dropping it on your other hand or any other 
part of the body would induce temporary discomfort but not even result in a bruise. The exposed 
spinal cord, however, would receive an injury with a possibly life-long deficit of function. 
The CNS is also vulnerable to ischemia. After just a couple of minutes of anoxia, cellular 
physiology deteriorates to the point of irreparable damage to the tissue. Because traumatic 
deformation of the spinal cord commonly leads to microvascular injury, some of the detrimental 
effects of trauma to the spinal cord will be caused by ischemia alone (34). Normal physiological 
arterial pressure in humans can also be enough to cause structural damage to the tissue in the case of 
rupture of an artery in the CNS (e.g. in subarachnoid hemorrhage) (35).  
The vertebrae and ligaments surrounding the spinal cord protect the soft and vulnerable neural 
tissue from injury in most situations encountered in daily life. The structure of the spine represents 
a developmental trade-off between low weight and flexibility and protection of the neural structures. 
When studied in the laboratory, the breaking point for normal vertebrae for axial pressure is 3-4 kN, 
roughly 3-400 kg placed on top of the head in normal gravity (36,37). Real-life injuries are more 
complicated, with various angles of force and rotational or penetrating trauma, possibly lowering the 
force needed for injury.  
Most traumatic spinal cord injuries are the result of transport-related accidents and falls (38). 
The mechanism of injury supplies the forces needed to exceed the breaking point of many structures 
in the human body, including the spine. Injury to the spinal cord itself is often inevitable in trauma 
leading to an unstable vertebral fracture because the delicate neuronal tissue will suffer injury 
immediately if the spinal canal is compromised by surrounding structures. 
SPINAL CORD INJURY IS A MEDICAL EMERGENCY 
Because of the forces needed to injure the vertebral column to the point at which spinal cord injury 
occurs, traumatic spinal cord injury (SCI) is commonly part of multi-trauma. Therefore, in the 
immediate pre-hospital or emergency room setting, life-saving interventions are always prioritized 
such as optimizing airway, breathing, and circulation (39). A severe SCI high enough in the cervical 
cord (above C3) will require artificial ventilation within minutes after the injury for the patient to 
survive, and the patient will be dependent on ventilator support throughout life. However, for any 
ACUTE SCI
Illustration MRI findings in acute SCI showing fractured vertebrae with
disc herniation and contusion with hemorrhage in the thoracic spinal cord
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patient in whom vertebral column injury cannot be excluded, great care must be taken to avoid 
inducing or worsening neurological damage by changing the anatomy of the fracture by 
mobilization. Therefore, all trauma patients should be put on a spine board to immobilize the spine 
until injury has been ruled out (40). 
In most clinical guidelines for severe trauma, patients undergo computerized tomography (CT) 
of the entire vertebral column at an early stage. CT testing has high sensitivity to vertebral fractures, 
catching the majority of suspected spinal cord injuries even in unconscious patients. Plain X-ray can 
miss some vertebral fractures and is not recommended (41). 
A small portion of spinal cord injuries occur without injury to the vertebral column and with 
injury to spinal ligaments and spinal cord alone (2 out of 45 in a recent Stockholm cohort) (42). If 
such a patient is unconscious from concomitant injuries, an MRI would be needed to find the injury. 
Therefore, in unconscious trauma patients for whom intubation is required, fiber optic intubation 
without the need for mobilization of the patient’s neck is recommended (43). 
If a spinal cord injury is confirmed or suspected, an early MRI should be performed. 
Advantages of early MRI include a definite diagnosis as well as the possibility for outcome prediction 
based on the MRI findings (44). MRI can also indicate whether the spinal cord is under pressure 
from surrounding structures or hematoma and provide clarity for early decompressive surgery. 
If the spinal cord is under pressure from surrounding structures, preclinical evidence strongly 
suggests and clinical studies indicate that early decompressive surgery improves neurological 
outcomes but also decreases the risk for other complications. Also, avoiding hypotension and 
hypoxia improves outcome in preclinical studies and is being tested in a clinical trial (40). 
Methylprednisolone is often given in an initial high-bolus dose (30 mg/kg) and then a 
continuous infusion for 24 hours (5.4 mg/kg/hour), despite contradictory evidence (45–47).  
Acute SCI represents a significant challenge for the health care system. In low-income settings, 
in-hospital mortality after SCI can be as high as 35%; in high-income regions, in-hospital mortality is 
around 8% (48). At present, early surgery for decompression with support and stabilization of vital 
parameters are the only truly evidence-based interventions in acute spinal cord injury. 
SPINAL CORD INJURY IS CLASSIFIED BASED ON LEVEL AND SEVERITY 
Spinal cord injury in a patient is classified based on segmental level of injury and severity of injury. 
Injury to the cervical spinal cord affecting both legs and arms is called tetraplegia, and injury to the 
thoracic or lumbar spinal cord affecting the legs is called paraplegia. Complete injuries show no 
voluntary function or sensation below the neurological level of injury, and incomplete injuries have 
varying degrees of function spared. 
For more precise classification of spinal cord injury, most health care systems (including the 
Swedish) use the American Spinal Injury Association (ASIA) and International Spinal Cord Society 
(ISCOS) International Standards for Classification of Spinal Cord Injury (ISNCSCI) assessment 
form (asia-spinalinjury.org/wp-content/uploads/2016/02/International_Stds_Diagram_Worksheet.pdf). The 
ISNCSCI form and published instructions detail the testing and classification of patients with spinal 
cord injury in a structured manner (49). The form defines the segmental sensory level by light touch 
and pinprick and the motor level by grading of strength. Each segment tested renders a point score, 
adding to the sensory score and motor score. The neurological level of injury is defined as the most 
caudal (toward the tail) neurological segment showing normal sensation and antigravity muscle 
strength. Further, completeness of the injury is tested by evaluating sacral sparing. If no voluntary 
anal contraction and no sensation to deep anal pressure are present, the injury is termed complete. 
Thereafter, the specific ASIA Impairment Scale (AIS) level is determined. 
  
Tetraplegia 71% 
Paraplegia 29%Respiration
C3-C5
Arm/Hand
C5-T1
Trunk
T1-L1
Leg
L2-S2
Urogenital
S2-S5
CLASSIFICATION OF INJURY
16% incomplete
13% complete
58% incomplete
13% complete
  13 
The AIS-levels are defined as follows: 
 
AIS-A encompasses sensorimotor complete injuries, defined as no sacral sparing and no residual 
muscle function more than three segments below the neurological level of injury. 
 
AIS-B encompasses sensory incomplete injuries showing sacral sparing of sensation but no 
voluntary anal contraction and no residual motor function more than three levels below the 
neurological level of injury. 
 
AIS-C encompasses motor incomplete injuries showing voluntary anal contraction and sensation 
or sensation to deep anal pressure and residual muscle function more than three levels below the 
neurological level of injury. 
 
AIS-D encompasses motor incomplete injuries by the same definition as AIS-C but with significant 
residual motor function in which more than half of the muscles below the neurological level of injury 
have antigravity muscle strength. 
 
AIS-E encompasses patients with a history of spinal cord injury and previous higher AIS 
classification but normal sensory and motor scores on examination with the ISNCSCI assessment 
form. 
 
The ISNCSCI assessment form gives clinicians and researchers all over the world a common language 
of classification for patients with spinal cord injury and enables patient stratification and observation 
of improvement or deterioration in neurological function. 
In the initial days after an SCI, the patient often presents with total areflexia below the injury 
level, referred to as spinal chock, which gradually transforms to spastic paresis with varying degrees 
of severity and level of spasticity (50). Because of the spinal chock, AIS-level scoring at three days or 
more after injury has higher predictive value for long-term AIS level than if assessed immediately after 
injury (51). Many patients experience improvements in function and even transitions in AIS grade 
months after injury, and such improvements have been recorded more than 12 months after injury, 
albeit rarely (51). 
INCOMPLETE CERVICAL SCI IS THE MOST PREVALENT INJURY TYPE 
A study performed prospectively in the greater Stockholm area from 2014-2015 identified 49 cases of 
SCI during an 18-month period and calculated crude incidence rates of 19.5 per million per year (42), 
which is consistent with other reports in the literature from regions with similar socioeconomic and 
demographic features (52). The median age in the Stockholm cohort was 58 years (range 18-85), and 
most injuries resulted in tetraplegia (32/45), with the majority of injuries being incomplete (25/32, 
AIS B-D). Of the injuries resulting in paraplegia, 6/13 were complete (AIS A). 
Almost all of the 45/49 injuries included in further analysis (44/45) from the Stockholm cohort 
were caused by transport-related events (18/45) and falls (26/45). Of the transport-related injuries, 
the most common causes were motorcycle accident (9/18) and bicycle accident (7/18). Among the 
falls, the authors reported an interesting stratification by age: 8/10 falls in the age group under 60 
years were from higher than three meters, whereas 12/14 falls in the age group over 60 years were 
same-level falls from under one meter (42). 
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Compared to a similar study in the Stockholm region in 2006-2007, the injury panorama for SCI has 
drifted, with a decrease in sports injuries and an increase in older women suffering incomplete 
cervical injuries from same-level falls (42,53). 
A recently published study utilizing data from the Global Burden of Disease (GBD) project—
in which data from 195 countries are continuously gathered and made available for researchers around 
the world—estimated that 0.9 million spinal cord injuries occurred worldwide in 2016, and 27 
million people were living with chronic spinal cord injury worldwide at that time (38).  
The same study calculated that the age-standardized incidence was 13 per year per 100,000 
people with a prevalence of 368 per 100,000 globally. In Sweden, as well as other high-income 
countries, spinal cord injury was more common according to the study: the age-standardized 
incidence was 26 per year per 100,000 people, and the prevalence was 903 per 100,000 people. The 
study estimated that 101,000 people are living with spinal cord injury in Sweden. These figures are 
inflated by a factor of 10 compared to the crude incidence rates reported by Joseph et al. (42) and by 
about the same amount when compared to other published reports of the demographics of SCI (38). 
The reason for this difference in incidence when using these separate methodologies is unclear and 
under investigation (personal communication with the author). 
REHABILITATION AND SPECIALIZED CARE ARE VITAL AFTER INJURY 
After the patient is medically stable, rehabilitation should start as soon as possible to prevent 
secondary complications and maximize function following injury. Rehabilitation has been shown in 
experimental studies to be vital for inducing plasticity and increasing recovery of neurological 
function after SCI in e.g. rats (54). In humans, high-level evidence of the positive effect of 
rehabilitation on neurological outcome is lacking, but the association is universally accepted (55). 
Rehabilitation also serves many other objectives such as improving the patient’s independence in 
activities of daily living and identifying and treating secondary complications. Recent studies on 
rehabilitation generally focus on type and timing of rehabilitation, but the level of evidence for a 
specific strategy is currently low (55). An emerging concept is robotic-assisted rehabilitation, by which 
the movements if rehabilitation are specifically controlled and supported to be physiologically 
beneficial (56,57). This strategy has yet to be proven to be superior to conventional rehabilitation 
with a physiotherapist, but it has the advantage of being standardized and the possibility of 
measuring improvements in areas such as weight-bearing more precisely. 
The enormous improvements seen in survival of patients with SCI during the 2000th century 
(58) is most certainly not only attributed to medical technology such as antibiotics but also to the 
establishment of specialized rehabilitation units actively following patients and treating 
complications preemptively. The following section describes some of the complications commonly 
seen in chronic SCI. 
BLADDER PROBLEMS ARE COMMON AND CHALLENGING 
In the period of spinal shock, the urinary bladder is commonly paretic, and severe urinary retention 
ensues if the bladder is not emptied. If not treated, increased pressure can result in kidney damage. 
With time, varying degrees of reflex micturition, leaking bladder, or normal urinary function appear.  
A higher risk for urinary tract infection and urosepsis prevails in the SCI population throughout life. 
Clean intermittent catheterization is commonly used for bladder management because it greatly 
reduces the risk for infection compared to indwelling catheters (59). Bladder management is an 
absolute necessary intervention. In an older study from the UK from 1992, urinary tract infection 
was the leading cause of death in the population with chronic SCI (24.3%), even higher than for 
 16 
cardiovascular disease (23.2%) (60). These numbers were greatly reduced during the 1990s and 2000s 
to 6-8% (61). 
Bowel function is also impaired after injury and can cause both constipation and fecal 
incontinence but usually does not result in the sort of life-threatening complications seen with 
bladder dysfunction (62). 
SEXUAL FUNCTION IS PRESERVED BUT OFTEN ALTERED 
The overall impact on sexual function after SCI is dependent on the location and severity of the 
injury, as well as on other SCI-related complications such as incontinence, spasticity, or pain (63,64). 
Subjective arousal can be experienced by SCI patients independently of the level of injury (65)m=, 
whereas (reflexive) genital responses such as lubrication in women and erection in men is commonly 
affected to some degree (64). In sacral injuries, it can be absent; in higher injuries, a reflex response is 
usually present (64). Erection in men can be supported with common medications for erectile 
dysfunction, and this intervention has been shown to increase HRQoL (66,67). The sexual act itself 
is also possible to conduct independent of the SCI but might need adaptations in order to be 
compatible with the limitations caused by the injury. For the partner of a SCI patient, this might 
involve modifications of previous sexual routines. Orgasms are commonly absent or different 
compared to pre-injury but are more often preserved among female patients. This is true even in 
complete injuries, possibly due to vagal innervation of the cervix (68,69). In a study of all 
Scandinavian community-living women with SCI, only 8% did not experience orgasms post-injury 
(70). In men with SCI, ejaculation is often not possible, or retrograde ejaculation occurs because of a 
lack of coordination after injury, with anejaculatory infertility as consequence (71). Ejaculation can, 
however, be elicited in more than 50% of men with complete injuries using vibratory stimulation of 
the penis and perianal area (72,73). Semen can then be retrieved for IVF, and direct intravaginal 
insemination in the home setting has led to pregnancies in a significant number of cases (71).  
In summary, sex continues to be an important aspect of life after SCI (64). Yet, the sexual 
experience is often altered, and the SCI patient and his or her partner need to develop a new sexual 
routine. Importantly, sex for reproductive purposes is often possible. 
PRESSURE ULCERS ARE POSSIBLE TO PREVENT 
Pressure ulcers are another common complication of SCI because of immobility and loss of 
sensibility. Although common, it is completely preventable both short- and long-term, as shown 
more than 50 years ago in an SCI center in the UK (74). Recent advances include electronic pressure 
sensing and feedback to the patient that adjustment of position is warranted to avoid pressure ulcers 
(75,76). 
SPASTICITY CAN HAVE BOTH POSITIVE AND NEGATIVE EFFECTS 
After the loss of supraspinal input to the spinal cord circuitry, an increased reflex activation of spinal 
motor neurons commonly occurs after SCI and other events such as stroke. This leads to the clinical 
manifestation of spasticity where the paretic body part produces involuntary movement, often in 
response to a sensory stimulus (77). The spastic muscles after SCI show increased tonus and a change 
in fiber composition (78). 
Clinical measurements of spasticity in SCI are negatively associated with Health Related 
Quality of Life (HRQoL) because it can interfere with movement and social functioning (79), but 
they are also positively associated with muscle mass below the injury level (80). Although mostly 
negative for the patient, spasticity can also be positive when a higher tonus of musculature leads to 
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findings like improved trunk stability, better weight-bearing for stepping in incomplete injuries, or 
stronger reflex genital response (77). 
NEUROPATIC PAIN IS COMMON AND DIFFICULT TO TREAT 
Pain is a common problem after SCI. Pain can arise for a number of different reasons such as 
immobility or bad seating in a wheelchair, but the most challenging is neuropathic pain. A Swedish 
study found a prevalence of neuropathic pain of 40% in spinal cord-injured patients of all levels and 
severity (81), and these figures are in line with other reports from the literature (82). The strongest 
predictor of neuropathic pain in the Swedish study was older age, and 70% of patients experiencing 
neuropathic pain stated that the pain was a problem in their daily life (81). 
Neuropathic pain can arise in a variety of conditions in the nervous system such as stroke, 
Parkinson’s disease, and peripheral nerve injury. Some form of lesions in sensory pathways is 
considered necessary, and neuropathic pain is usually not encountered where sensation is normal 
(83). One study in spinal cord-injured patients showed that neuropathic pain was most prevalent in 
patients with small residual spinothalamic function (84). 
Management of neuropathic pain can be challenging because many common pain medications 
are ineffective, and some have problematic long-term effects (83). A recent Canadian consensus (85) 
developing clinical guidelines for the management of neuropathic pain in SCI suggests using the 
International Spinal Cord Injury Pain Basic Data Set (86) for classification and follow-up of 
neuropathic pain. The same consensus group published detailed clinical guidelines for treatment, 
advocating first-line medical treatment as follows: first pregabalin, thereafter gabapentin, and then 
amitriptyline (82). 
AUTONOMIC DYSREFLEXIA CAN BE DANGEROUS 
SCI patients with a neurological level of injury above the midthoracic level (commonly cited as 
injuries above T6) show a varying tendency to develop autonomic dysreflexia. The condition is most 
often seen in tetraplegic patients, and is a potentially life-threatening condition characterized by a 
sharp increase in blood pressure well over 200 mmHg (87). Normal systolic blood pressure in this 
patient group is commonly under 100 mmHg (87). It has been reported to result in seizures, cerebral 
hemorrhage, and sudden death (88–90). Autonomic dysreflexia is thought to be triggered by noxious 
stimuli or an imbalance in the paretic part of the body such as bladder distension (87,90), but the 
precise pathophysiological mechanism is still debated (91). Blood pressure measurements of SCI 
patients have shown that sharp variations of blood pressure are much more common than the 
episodes of severe hypertension noted by patients and health care professionals, and they are 
implicated as an explanation for the increased cardiovascular risk seen in some groups of SCI patients 
(92). Therefore, novel methods for measuring and detecting the blood pressure variations seen in SCI 
are under investigation (93). 
LIVING WITH CHRONIC SPINAL CORD INJURY 
Defining the impact of SCI on an individual can be done in many different ways such as describing 
the neurological function in the patient (49), analyzing mortality (58), and tracking the incidence of 
medical complications such as urinary tract infections (94), fertility (71,95), years lost to disability (38), 
and employment status (96). 
After the acute phase, mortality rates in the SCI population continue to be increased (48), but 
life expectancy in chronic SCI varies strongly with injury level and severity. In AIS-D, life expectancy 
is the equal to that in the normal population. In AIS A-C, high cervical injuries (C1-C4) have about  
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65%, low cervical (C5-C8) have 70%, and T1-S5 have 90% of the life expectancy of the normal 
population (97). Respiratory infection was the most common cause of death (29.2%) from 2004-2015 
in a cohort of chronic SCI patients studied in the UK, followed by cardiovascular (21.8%), neoplasms 
(15.9%), and urogenital disease (8.7%) (61). Depression is more prevalent throughout life after SCI 
than in the normal population (98), and the Global Burden of Disease recently estimated that years 
lost to disability are similar in SCI as in traumatic brain injury, despite traumatic brain injury having 
a 30-times higher incidence rate (38).  
An important aspect of SCI not covered by these measures is the subjective experience of living 
with SCI and Health-Related Quality of Life (HRQoL). Subjective experience can be analyzed by 
measures such as qualitative interview-based methods and give fundamental insight into important 
aspects of human experience and behavior (99). Although an important strategy, findings across 
studies—even within the same patient over time—can be hard to compare in a quantitative fashion. 
Structured or semi-structured instruments for HRQoL such as the EQ-5D or more extensive 
instruments can overcome this problem and have been used in SCI (100,101) and many other 
neurological conditions (102). 
Measurements of HRQoL consistently show a decrease after SCI, often in connection to 
medical problems (94,100,103,104). To account for and measure adequate health-related quality of 
life data in the SCI population more efficiently, a recent effort (called SCI-QOL) has created specific 
but adaptive questionnaires with the ability to measure quality of life at the current level of 
functioning in an SCI patient (105). This approach has an advantage over instruments developed for 
the general population because it captures specific issues after SCI in greater detail and avoids 
questions that are irrelevant or even offending (105). Unfortunately, it has not yet been translated 
and validated in the Swedish language. 
The priorities of individuals living with chronic SCI have also been studied: for tetraplegic 
patients, regaining arm function is the highest priority, whereas for paraplegic patients, sexual 
function is the highest priority. Bladder and bowel control rank high for both paraplegic and 
tetraplegic patients. Thus, contrary to popular belief, walking is not the highest priority in the SCI 
population and often ranks third or fourth place (106). A meta-analysis of priorities largely reflected 
the result from the study by Anderson in 2004, but emphasize the impact of how questions are asked, 
and the injury level and severity in the patient group answering the question (107). 
In conclusion, spinal cord medicine has improved greatly during the last decades, boosting life 
expectancy and the arsenal of battling chronic medical problems after SCI, although similar goals 
apply today, as stated more than 50 years ago by one of the early pioneers of spinal cord injury 
medicine Sir Ludwig Guttman, preventing common medical problems and supporting the patient 
through physical and occupational rehabilitation to a meaningful and productive life (74).  
Hemorrage
and ischemia
Axonal
damage
Edema
Pressure from
hematoma
ACUTE INJURY
  21 
BIOLOGICAL MECHANISM AND CLINICAL TRIALS IN SCI 
PRIMARY INJURY LEADS TO IMMEDIATE LOSS OF FUNCTIONS 
As described in an earlier section, the tissue of the spinal cord is both soft and brittle and is injured 
by a small mechanical insult. Shattering of the complex organization of the neural tissue leads to loss 
of axonal connections and cell rupture at the very moment of the injury. As a result of microvascular 
injury, disruption of oxygen and nutrient supply quickly expands cell death beyond the momentary 
loss of structures. In experimental injury, cell death in both neurons and glial cells begins immediately 
after contusion injury and levels out after about four hours (108). 
In clinical SCI, the initial impact is often followed by delayed pressure due to displaced 
surrounding tissue, swelling of the injured spinal cord, or hematoma (109). Experimental studies in 
animals have shown that delayed pressure to the cord results in worse neurological outcome by a 
factor of time and pressure and that early decompression can rescue the negative effect (110). Several 
publications on clinical SCI cases have shown clinical benefit in terms of long-term neurological 
outcome in patients undergoing early decompressive surgery, with recent definitions of “early” being 
within eight hours after trauma (111–113), but to date no randomized trial has been completed (114).  
Increasing spinal cord blood flow by elevation of mean arterial pressure and cerebrospinal fluid 
drainage has been shown to improve outcomes in experimental SCI in the pig (115). A phase I/II 
clinical trial showed safety but failed to show efficacy due to lack of power (116); a phase II/III study 
is ongoing (NCT02495545). 
Lowering tissue demand of oxygen and nutrients by hypothermia has been suggested for many 
conditions including acute SCI. Modest hypothermia (32-34°C) has been shown to be safe (117), and 
a randomized clinical trial has been planned but not yet performed (118). 
Measurement of biomarkers in serum and CSF after traumatic brain injury have led to 
important advances in clinical management and outcome prediction (119,120). Recently, a set of 
biomarkers collected from CSF drainage (when studying the effect of CSF drainage mentioned 
above) was shown to predict AIS grade after injury, even surpassing the predictive power of MRI 
(121). 
Prevention of further ischemic injury, delayed primary injury by early decompressive surgery, 
and prevention of hypoxia and hypotension are the only current medical interventions for 
ameliorating the primary injury at present, and hypothermia is a potential future acute intervention 
if efficacy can be proven (118). Apart from this, primary prevention strategies in society are the only 
feasible interventions for battling primary injuries because of the short time frame from physical 
insult to manifest injury. 
CNS WOUND HEALING RESULTS IN SECONDARY INJURY AND A GLIAL SCAR 
Mechanical injury to cell membranes and microvasculature with necrotic cell death and disruption 
of the blood-brain barrier starts a cascade of events, with important functions for preventing 
infections, clearing tissue debris, re-establishing the blood-brain barrier, and re-establishing tissue 
homeostasis (122). After the acute physical insult resulting in an SCI (or injury to the CNS in general), 
there is clear evidence of a secondary injury in which further loss of neurons, axons, and myelin occurs 
(118,122,123). This phase last hours to weeks after injury and is characterized by activation of the 
immune system; inflammation; proliferation of glial cells, endogenous stem cells (124) and pericytes 
(125), and upregulation of extracellular matrix proteins. The secondary injury cascade matures into 
what is commonly termed “the glial scar” (126,127).  
Immediately after injury, disruption of the blood-brain barrier, hemorrhage, and apoptosis 
trigger microglia proliferation as well as infiltration of blood-derived neutrophils and macrophages.  
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Immune cells protect the tissue from infection in non-sterile wounds, and phagocytizing cells clean 
debris and necrotic tissue and stimulate angiogenesis in the injury zone (122). The immune reaction 
also produces a powerful inflammatory response through release of pro-inflammatory cytokines 
including IL-1β and TNF-α in the tissue with further damage to neurons and glia (122). In the early 
phase, blood derived macrophages rather than microglia has been suggested as the main culprit in the 
secondary dieback of axons rather than resident microglia (128). Microglial response has sometimes 
been attributed to a pro-inflammatory cytotoxic phenotype (M1) and an alternative activation (M2), 
but inconsistent findings and single-cell RNA sequencing have resulted in a vastly more complex 
understanding of microglial phenotypes both in normal physiology and in injury (129). 
The initial inflammatory response to injury triggers proliferation and migration of glial cells 
into the lesion via mainly chemokine signaling (127). Astrocytes and cells positive for the marker NG-
2 have been studied extensively as they proliferate and differentiate (130). One study showed that the 
initial astrocyte response supported axon regeneration during the first two weeks after SCI in mice, 
but further exposure of the astrocytes to mainly collagen-1 (usually not present in the CNS) 
transformed astrocyte response into a scar-forming phenotype that inhibited regrowth of axons (131). 
Abolishing the astrocyte response was also associated with worse neurological outcome in mice (132). 
Another recent advance in the understanding of astrocytic response to injury in a shorter time frame 
after injury is the identification of the neurotoxic A1 subtype activated by reactive microglia through 
the cytokines Il-1α, TNF, and C1q (133,134). A1 astrocytes, in contrast to the A2 phenotype, were 
shown to lose many normal astrocytic functions and induced death of neurons and oligodendrocyte 
in vitro.  
In mouse contusion SCI, NG-2-positive cells of oligodendrocyte origin differentiate and form 
25% of the astrocytes in the glial scar (135). Another NG-2-positive cell (type A pericytes) has also been 
shown to proliferate extensively after injury and promote physical closing of a spinal cord injury 
lesion (125). Abolishing the pericyte response led to worse functional outcome after injury (125), but 
a balanced reduction of the response promoted recovery in mice after spinal cord injury (136). 
During the first weeks after injury, the proliferation of astrocytes, oligodendrocyte progenitors, 
and pericytes leads to marked increase of production of a class of extracellular matrix proteins called 
chondroitin sulphate proteoglycans (CSPGs) (126). These have been shown to play a major role in 
inhibition of axonal outgrowth and the enzymatic breakdown of CSPGs by application of the 
bacterial enzyme chondroitinase, which is associated with recovery of function after injury (137,138). 
Another important inhibitor of axon outgrowth after injury is the myelin-associated neurite 
outgrowth inhibitor termed NOGO (139). 
CLINICAL TRIALS TARGETING SECONDARY INJURY AND GLIAL SCARRING 
For good reasons, the majority of interventional clinical trials in SCI have focused on the subacute 
phase in order to minimize secondary injury. Despite preclinical success, all pharmaceutical 
interventions that have completed phase III to date have failed to show efficacy for the primary 
endpoint. Some promising approaches are in earlier phases of clinical trial or in ongoing phase III. 
Methylprednisolone is a potent immune suppressor, and observations of anti-inflammatory 
effects potentially alleviating edema and the secondary injury cascade led to its use in the acute phase 
of spinal cord injury. Despite five RCTs with negative results in the primary outcome (45–47) and a 
significant increase in adverse events, there is still debate about its use because of beneficial effects 
seen in a subgroup of severe injuries receiving the treatment within eight hours after injury 
(47,118,140). Ganglioside, a cell membrane component, was initially successful in animal experiments 
and phase II trials but failed to show efficacy in phase III (141). Nimodipine, a calcium channel 
blocker, also failed in RCT (142), and so did gacyclidine (143). 
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A number of potential candidates are currently in the translational process. Magnesium has shown 
preclinical efficacy (144), but a phase I/IIa trial was recently terminated by the sponsor due to 
insufficient enrollment (NCT01750684). SUN13837, a mimetic of basic fibroblast growth factor, 
recently completed phase I/IIa showing safety but not efficacy (145). 
Anti-NOGO antibody has been tested and shown efficacy in many preclinical models of SCI 
(146–148) and was recently shown to be safe in phase I/IIa (149). Minocycline, an antibiotic, has been 
shown to be safe, and a trend towards positive outcome in cervical SCI was demonstrated in phase II 
(150). A phase III trial is recruiting patients but not completed (NCT01828203). Riluzole is a 
glutamate blocker currently registered for amyotrophic lateral sclerosis that has shown efficacy in 
animal models of SCI (151) and was proven to be safe in a phase I study (152). A phase II/III study is 
currently recruiting (NCT01597518). Cethrin/VX-210 has promoted axonal outgrowth after injury 
through blocking axonal growth inhibition via the Rho-ROCK pathway (153). A phase I study 
showed promising results when applied in fibrin sealant during decompressive surgery in the acute 
phase (154); an IIb/III study has been completed, but results have not been published 
(NCT02669849). Implantation of a bioresorbable polymer scaffold with known preclinical efficacy 
has been performed in a patient during acute decompression surgery (155); a clinical trial is ongoing, 
and 19 patients has been enrolled (NCT02138110). 
Injection of stem cells for the treatment of spinal cord injury has shown preclinical potential 
across a wide variety of injuries, time points, and species (156–158). The approach has been proposed 
and tested for several decades, but has not resulted in approved interventions to date for SCI, despite 
clinical trials (159,160). Because positive effects have been seen after stem cell injections in the acute 
phase after experimental SCI despite limited number of cells surviving in the long term, it has been 
speculated that for some applications, the positive effect of stem cells could be purified and similar 
results obtained without the injection of cells. For other motives such as cell replacement of motor 
neurons lost in a cervical SCI, a stem cell graft is an attractive concept despite its many challenges 
(156).  
WHEN FUNCTION IS LOST AND THE GLIAL SCAR ESTABLISHED 
Scarring in many other parts of the body is functional, and the scarred tissue can acquire function to 
near pre-injury conditions. In humans and rats, a spinal cord injury commonly results in a post-
traumatic fluid-filled cyst (161). The glial scar is found in the interface between cyst and normal spinal 
cord; it is thin (162) and, contrary to earlier belief, even softer than normal CNS tissue (163). The glial 
scar is important for reestablishing the blood-brain barrier and preventing further damage to tissue, 
but the resultant molecular environment of the glial scar makes regeneration of neurological function 
impossible (126,127). Regeneration attempts by injured axons fail, resulting in characteristic 
dystrophic end bulbs described by Cajal in the beginning of 20th century (164). These are commonly 
in direct contact with NG-2-positive cells via CSPG receptors (126). 
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CNS AXONS CAN BYPASS THE GLIAL SCAR IN PERIPHERAL NERVE GRAFTS 
The failed attempts of CNS axons to regenerate spontaneously through the glial scar after injury were 
known more than a century ago and described in detail by Cajal and others (164,165). Researchers at 
the time also recognized that severed axons in the peripheral nervous system had an intrinsic capacity 
for regenerating and re-establishing lost function, and that injured axons in the CNS would 
regenerate into peripheral nerve grafts positioned in the lesioned CNS. For an inspiring historical 
background, see the thesis by Fraidakis (166). 
In the 1980s, the concept of CNS regeneration through peripheral nerve grafts was rediscovered 
and further characterized (167–169). In 1996 Cheng and colleagues further refined the experimental 
protocols by routing regenerating axons from white matter to grey matter on the opposite side of a 
complete thoracic spinal cord lesion by using autologous nerve grafts and adding fibroblast growth 
factor 1 (FGF1) in fibrin glue to increase neuronal sprouting (170). With this method, adult rats 
subjected to complete thoracic spinal cord transections regained some hindlimb function with time. 
Electrophysiological evidence and histological evidence of re-establishment of connections across the 
complete SCI were also present. The method has since shown similar results when performed in 
chronic complete injury (171), which is in line with the observation that a chronically injured axon 
will begin sprouting again after a re-axotomy of the dystropic end bulb after regeneration failure 
(172). The bridging strategy has also been repeated in several other labs (173–175), and similar methods 
of bridging with peripheral nerves in the spinal cord have been performed in a variety of experimental 
(176–178) and clinical (179–182) settings. Unfortunately, none of the clinical series reported in the 
literature has been designed as randomized controlled trials, and the level of evidence is therefore low. 
A limitation for clinical translation of the pioneering work by Cheng et al. (1996) is the 
requirement of meticulous placement of the peripheral nerve grafts on the spinal cord transection’s 
surfaces. Therefore, Nordblom et al. further developed the method (183) and finally applied a 
biodegradable guiding device made from calcium sulphate (184). The guiding device could be soaked 
in FGF1 and showed slow release of the growth factor during degradation (185). In rats subjected to 
complete thoracic spinal cord resection, the device-guided precision grafting resulted in robust return 
of electrophysiological response in hindlimbs, histological evidence of axonal regeneration, and some 
regain of hindlimb function (184). The minimal required dose of FGF1 in rats was also tested, 
showing that 7 ng was needed for return of motor-evoked potentials at four weeks after injury (186). 
Encouraged by preclinical success in re-establishing connection across a complete thoracic spinal 
cord injury with autologous peripheral nerve grafts in a biodegradable guiding device, we set out to 
translate the preclinical method described by Cheng et al. and refined by Nordblom et al. to a clinical 
trial in SCI patients. 
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OBSTACLES IN CLINICAL TRANSLATION OF A REGENERATION STRATEGY 
In clinical trials, the safety of research subjects is the most important concern. Because of the anatomy 
of the spinal cord and the location of eloquent function, patients with complete (AIS-A) chronic 
spinal cord injury in the thoracic spinal cord are referred to as the “preferred patient group for clinical 
trials” (187,188). In the thoracic spinal cord, an unexpected adverse effect of the study intervention is 
the least likely to cause harm or deteriorate neurological function. This produces an important 
contradiction because no segmentally isolated key muscle function can be produced in 
approximately segments T2-L1 with clinical examination, and therefore determining the precise 
motor level is more or less impossible. This means that monitoring motor function in a clinical trial 
involving subjects with complete thoracic SCI is not possible with clinical examination alone. 
Additionally, knowledge of the caudal demarcation of the spinal cord injury is vital when applying a 
method that relies on re-establishment of connections across an injury gap. Anatomical evidence can 
be gathered with MRI, but a functional indicator of the extent of the injury would be required for 
reliable estimation of the length of the injury. 
Further, applying a pre-fabricated medical device during surgery aiming to fit the cross-sectional 
surface of the spinal cord requires that the exact dimensions of the spinal cord is known in advance, 
either by non-invasive measurement (e.g. with MRI) in a patient or by producing a set of devices in 
different sizes covering the normal variability. Because the resolution of spinal cord MRI is currently 
insufficient when spinal instrumentation is present because of metal artefacts, the only remaining 
option is exact knowledge of spinal cord cross-sectional dimensions and variability. The literature 
contains several reports on spinal cord morphometry, but unfortunately different studies use diverse 
reference points for measurements, and the reported sizes of spinal cord varies considerably between 
studies. 
To redesign the preclinical guiding device for a clinical trial, knowledge of cross-sectional size 
and variability of the human spinal cord would have to be combined with data on spinal tracts in 
humans for a resulting final design and sizing of a guiding device adapted for human SCI while 
retaining the key concepts from successful preclinical studies. 
Reaching clinical trial in a translational process is a significant and collaborative undertaking 
requiring co-operation of multiple institutions, professions, and funding sources; rigorous external 
control of data quality; and safety of study subjects. The first and foremost concern is the safety of 
research subjects, and therefore thorough and early reporting of adverse events is of importance. 
Additionally, in a clinical trial evaluating a biodegradable medical device, confirming degradation of 
the device in the study subjects is pivotal. 
Also, for the advancement of microscopic knowledge of spinal cord injury biology, lowering 
the cost of establishing a light-sheet microscope could make the technique more accessible for the 
research community. 
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AIMS 
 
 
 
The overall aim of this thesis was to aid the preparation for clinical translation of a regeneration 
strategy for chronic and complete thoracic spinal cord injury by means of glial scar resection and 
autologous nerve graft transplantation using a biodegradable scaffold soaked in fibroblast growth 
factor 1. 
 
 
Specifically, we sought to: 
 
1) Develop a clinical neurophysiological method for precise investigation of segmental 
motor function in the thoracic spinal cord (paper I) 
 
2) Define continuous estimates of human spinal cord segmental cross-sectional 
diameters and standard deviations from the literature (paper II) 
 
3) Design a biodegradable guiding scaffold for human thoracic spinal cord dimensions 
and define a set of sizes covering the variability in size encountered in humans (paper 
III) 
 
4) Describe the early adverse events in the ongoing clinical trial “Safety and Efficacy of 
SC0806 (Fibroblast Growth Factor 1 and a Device) in Traumatic Spinal Cord Injury 
Subjects” and the biodegradation of the guiding scaffold as observed by computerized 
tomography (paper IV) 
 
 
For more precise investigation of spinal cord pathology and potential future attempts to expand 
spinal cord regeneration to for example incomplete or cervical injuries, we also endeavored to: 
 
5) Construct a cost-effective light-sheet microscope by modification of an outdated 
microarray scanner for whole-mount imaging of central nervous system tissue (paper 
V)
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MATERIALS AND METHODS 
FORMAL APPROVAL OF THE RESEARCH 
Papers I and IV involve human subjects. Both studies were approved by the Independent Ethics 
Committee in Stockholm (Etikprövningsnämnden) under permit 2010/344-31/2 (paper I) and 
permit 2013/2257-31/1 and 2015/1436-31 (paper IV). The study reported in paper IV was also approved 
by the Swedish Medical Products Agency Study Protocol SC0806-A101, version 10 
EudraCT number 2013-000906-52, and registered at ClinicalTrials.gov under identifier 
NCT02490501 before the inclusion of study subjects. The study detailed in paper IV is ongoing, and 
only short-term safety and degradation of the guiding device is reported in paper IV. 
Studies I and IV were performed at Karolinska University Hospital, Solna in the departments 
of Neurosurgery, Neurology, and Neurophysiology. Initial screening, follow-up, and rehabilitation 
in study IV was performed at the Spinalis Foundation, Solna. Radiology was performed at the 
Karolinska University Hospital, Solna and Radiology Center, Medicinsk Röntgen Hötorget, 
Stockholm. All subjects in papers I and IV signed written informed consent forms prior to 
participating in the studies. 
Paper V involved rats as experimental animals. The study was approved by the regional ethics 
committee in Stockholm (Stockholms djurförsöketiska nämnd) under permit numbers N104/15 and 
14274-2017. All experiments were performed at animal facilities at Karolinska University Hospital, 
Solna. 
Papers II and III did not undergo formal ethical approval because they only involved data from 
already published sources. The ethics of papers II and III rely in part on the ethics of the published 
material used as data sources, which we have found no reason to question. 
HUMAN RESEARCH SUBJECTS (PAPERS I-IV) 
Paper I included five male subjects with complete chronic thoracic spinal cord injury (AIS-A) at levels 
T3-T7 recruited through the spinal cord injury ward at Karolinska University Hospital, Solna. 
Eligibility was based on medical records and clinical neurological examination. 
Paper II included data from 631 study subjects without spinal cord pathology gathered from 10 
published studies on spinal cord cross-sectional size (189–198), two studies on spinal cord neuronal 
segment length (197,199), three studies on human vertebral segment length (200–202), and two 
studies relating measures of the spinal cord and vertebrae (203,204). 
Paper III used the summary data calculated in paper II and added data from two published 
series of histological sections of two human spinal cords without spinal cord pathology (194,205). 
Paper IV describes early adverse events reported from the ongoing clinical trial “Safety and 
Efficacy of SC0806 (Fibroblast Growth Factor 1 and a Device) in Traumatic Spinal Cord Injury 
Subjects.” As of November 2018, nine subjects with complete chronic thoracic spinal cord injury 
(AIS-A) at levels T4-T11 have been included. Six were randomized to glial scar resection, 
implantation, and rehabilitation, and three were randomized to rehabilitation only. Study subjects 
were recruited through rehabilitation centers in Sweden. After initial screening and study 
information, subjects who give informed written consent and are provisionally eligible are further 
screened for eligibility at Karolinska University Hospital.   
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META-ANALYSIS AND DESIGN OF GUIDING DEVICE (PAPERS II AND III) 
Studies and data 
We searched PubMed for original research publications reporting morphometric data on the human 
spinal cord. Studies not found in PubMed but referred to in the included studies were also added. 
We included three studies presenting the length of the vertebral bony segments in table 1b (200–
202). 
To define the white-to-grey matter delineation in the thoracic spinal cord, we used two 
representative series of microscopic slides covering the entire human spinal cord segmentally found 
in the literature (194,205). The location of spinal tracts was estimated based on schematic 
representations found in the literature in combination with degeneration studies. 
Software and extraction of data from published studies 
Data were gathered in Microsoft Excel and stored as comma-separated values (.csv), all calculations 
were performed in R (206), and graphs were produced with the ggplot2 and cowplot packages 
(207,208). Bootstrapping was performed with the boot package (209). 
Most of the studies included did not present the raw data from their measurements; instead, 
averages and standard deviations were provided. Some of the studies did not present their data in 
numerical format but only in a graphical format. To ensure correct extraction of data from these 
studies, we imported images of the graphs into a CAD program (Rhino 5 for Mac, Robert McNeel 
& Associates) and used the internal measurements tool to extract the exact values from the graphs. 
All raw data, results from simulation, and codes are available upon request. 
Relative lengths of spinal cord neuronal and vertebral bony segments 
Using the data from the studies in table 1b, we calculated the relative length of each spinal cord 
neuronal segment by simply dividing the length of each segment by the total length of the spinal 
cord. When estimating the segmental diameter, the measurements from the different studies were 
weighted according to the number of subjects (i.e. individuals) in the respective study.  
Using the data from the studies in table 1b, we also calculated the relative length of each vertebral 
bony segment using the same method as for the neuronal segments described above. A vertebral 
bony segment was defined as the vertebrae and half of the two adjacent intervertebral discs. The discs 
were assumed to increase in size proportionally to the vertebrae. 
There were no measurements for vertebral segments C1 and C2 in the studies that we found. 
Their respective ratios were approximated by aligning vertebral bony segments with spinal cord 
neuronal segments in the cervical region according to Cadotte and colleagues (203). Specifically, the 
distance between the midpoint of spinal cord neuronal segment C3 and vertebral bony segment C3 
was set to 1.3 times the distance between spinal cord neuronal segments C3 and C4. Finally, we 
assumed that both the spinal cord and the vertebral column terminated at the same cranial level and 
divided the distance equally between C1 and C2 vertebral bony segments. Therefore, our calculated 
relative size of C1 and C2 should be considered approximations and interpreted with care. 
Relative positioning of spinal cord neuronal and vertebral bony segments 
To align the spinal cord neuronal segments with the vertebral bony segments, we multiplied all 
cumulative percentages for vertebral bony segments by 1.29. This scaling factor was calculated by 
dividing the cumulative percentage of the entire spinal cord (100%) with the cumulative percentage 
of the vertebral column at vertebral bony segment L1. This new scaling of vertebral bony segments 
set the caudal end of the L1 vertebral bony segment equal to the caudal end of spinal cord neuronal 
segment S5. The positioning depends on the knowledge of the relative positions of the C3 and C4 
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spinal cord neuronal segments to the C3 vertebral bony segment presented in the study by Cadotte 
and colleagues (203) and the level of termination of the spinal cord between vertebral bony segments 
L1 and L2 (204). 
The relative positions of the segments were used to find the correct relative positions of each 
cross-sectional measurement along a normalized craniocaudal axis of the human spinal cord. Each 
measurement was placed as closely to the anatomical position described by the original authors as 
possible with respect to the type of segmental reference used in the study (spinal cord neuronal 
segment or vertebral bony segment), as well as the positioning on that specific segment (cranial end 
of segment, midpoint of segment, or caudal end of segment). 
To estimate the effect of adjusting the craniocaudal position of measurements of the transverse 
diameter of the human cervical spinal cord, we fitted a linear regression model before and after 
correction of craniocaudal position: 
 
Transverse diameter ~ b1*position + b2*position2 + b3*study 
 
The squared term was added because the cervical spinal cord transverse diameter approximates the 
shape of a second-degree polynomial, and the dummy term study was added to correct for differences 
in intercept between the studies. Adjusted R-squared was used as a measure of alignment of the 
cervical intumescences between studies. Confidence intervals for adjusted R-squared were estimated 
using a 1000-iteration bootstrap. 
Weighted averages of spinal cord cross-sectional diameters and variance 
To combine the cross-sectional measurements of the human spinal cord from all studies into single 
estimates, we calculated a moving weighted average. First, measurements from all studies were 
aligned along their position on our corrected craniocaudal axis described above. Thereafter, starting 
at the cranial end, four consecutive measurements of spinal cord diameter were combined into a 
single average, weighted by the number of subjects in the underlying studies for the four included 
measurements. The average position along the craniocaudal axis of the four measurements was used 
as the new position for the weighted average. Next, the most cranial of the four measurements was 
dropped, and the closest measurement caudal to the three remaining measurements was included to 
create a new group of four measurements, with a new weighted average and a new position along the 
craniocaudal axis. 
Moving weighted variances were calculated using the same method as described for the moving 
weighted averages. The calculated variances were then converted to weighted standard deviations. 
Continuous estimates of spinal cord cross-sectional diameters and variance 
To construct continuous population estimates and achieve further smoothing, a generalized additive 
model was used to fit the weighted averages and weighted standard deviations. We used the 
smoothing function of ggplot2 (208) in R (206) with the formula y ~ s(x, k = 12), allowing for a 12-
degree polynomial function to fit the data. 
To facilitate comparison between our continuous population estimates and other studies, we 
extracted values for each spinal cord neuronal segment as well as each vertebral bony segment. The 
number of subjects measured for a given segment was defined as the total number of subjects 
included in any study with a calculated craniocaudal position inside the cranial and caudal limits of 
the segment in question. This was used as an approximation of sample size, as there is no obvious 
way of calculating exact sample size for different portions of a smoothing function. 
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Simulation of a population of spinal cord sizes 
To facilitate visualizations and calculations, the continuous estimates from paper II were used to 
generate a theoretical sample of spinal cords with the same mean and distribution as in the published 
paper. Two hundred samples per spinal cord level were generated using the mvrnorm()-function in 
R with the package “MASS” (206,210). The correlation of the bivariate Gaussian distributions 
generated was set differently for each segment in a continuous fashion, dependent on transverse 
diameter. These ranged from high correlation (0.9) in the small segments (sacral spinal cord) to lower 
correlation (0.4) in the large segments (cervical cord). This was done to satisfy the shape constraint 
observed in the raw data of spinal cord sizes (i.e. the spinal cord can be neither too “flat” nor too 
“round”) (197). 
Elliptical interfaces for guiding devices covering the thoracic spinal cord 
Given the continuous estimate of spinal cord segments T2 to T12, we chose seven elliptical shapes 
that covered these thoracic spinal cord segments by using three different ellipses with a ratio between 
anteroposterior and transverse diameter (RAPT) equal to the mean RAPT of the thoracic spinal 
cord (termed “normal” shape), an additional two ellipses with a rounder shape than the mean RAPT 
(termed “round” shape), and two ellipses with a flatter shape than the mean RAPT (termed “flat” 
shape). The ellipses were spaced symmetrically and placed to cover the central part of the population 
estimates. 
Another three large ellipses were added—one for each shape—to prepare for the event of spinal 
cord swelling due to surgical manipulation. These extra ellipses were not included in the error-of-fit 
calculations since they were intended as an extra safety measure. 
Error-of-fit between thoracic spinal cord segments and guiding devices 
To calculate the error of fit between our set of guiding device sizes and the simulated spinal cord sizes, 
we assigned each simulated spinal cord segment (between T2 and T12) to the best-fitting guiding 
device in our set of seven sizes. The best-fitting guiding device was chosen by attempting to minimize 
both transverse and anteroposterior difference between the simulated segment and the elliptical 
shape of the guiding device. This was accomplished by minimizing the square root of the sum of the 
squares of the transverse and anteroposterior error (equal to minimizing the Euclidian distance 
between the simulated spinal cord segment and the guiding device in a two-dimensional space 
representing transverse and anteroposterior diameter). After the best-fitting guiding device was 
chosen for every simulated spinal cord size, we calculated the transverse and anteroposterior error 
separately, as well as the mismatch in area. This was done for every simulated spinal cord segment, 
which resulted in 200 segments per level between T2 and T12 for a total of 2,200 simulated spinal 
cord sizes. 
Creating a vector model of the human spinal cord 
Images covering the entire human spinal cord were available in a digital format and were imported 
in a CAD program (Rhinoceros for Mac, version 5). The outline of the spinal cord and the 
delineation between white and grey matter were traced manually to create a vector model. The 
midline of the spinal cord was identified, and both traced halves were averaged to yield symmetric 
white-to-grey matter delineations for each segmental level of each spinal cord series. Furthermore, 
each segmental image was scaled to the average transverse and anteroposterior diameter for that 
segment using the data collected from paper II. Thereafter, segments T2 to T12 were averaged in both 
spinal cord series, and both thoracic averages were combined into a final average representation of 
the delineation between white and grey matter in the human thoracic spinal cord. 
  37 
Designing the guiding device interfaces and channels 
The device was designed in a CAD program (Rhinoceros for Mac, version 5). The guiding channels 
of the device were chosen using the vector model of the spinal cord and anatomical knowledge of the 
spinal cord tracts in humans. Channels were designed to start at a relevant descending (e.g. 
corticospinal tract) or ascending (e.g. dorsal column) tract and to run obliquely through the device 
to reach grey matter at the other side of the device. Channels were spaced so as not to intersect each 
other and to leave a wall of material of at least 0.4 mm between channels. 
Alignment of guiding device channels and spinal cord white matter tracts  
To assess the alignment of the device channels, the vector model of the average thoracic spinal cord 
and the guiding device interfaces were imported in R. The spinal cord shape was then scaled to the 
dimensions of each simulated thoracic spinal cord segment and overlaid on the shape of the device 
that showed the best fit for the particular simulated spinal cord segment. The results were assessed 
qualitatively. 
Determining the final set of guiding devices 
From the design process described above, we choose seven guiding device sizes and an extra three 
larger sizes for a total of 10 interface sizes. Because the spinal cord is mobile to some extent in the 
spinal canal, the length of the guiding device was chosen with 5 mm increments from 15 mm to 40 
mm, covering the shorter range of thoracic spinal cord injuries (211). This resulted in a total of 60 
guiding devices (10 interfaces x 6 lengths). 
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METHODS USED IN THE CLINICAL TRIAL (PAPERS I AND IV) 
Neurological examination 
Neurological examination was performed on all study subjects in papers I and IV by a senior 
consultant neurologist with experience in spinal cord injuries. The examination was performed 
according to the AIS classification. 
Neurophysiology 
The neurophysiological method used in paper I was also employed as part of the preoperative 
workup and inclusion criteria for paper IV. All examinations in both studies were performed by the 
same senior consultant neurophysiologist, blinded to the results from the clinical examination as well 
as imaging such as MRI and fMRI. 
In brief, bipolar needle electromyography (EMG) recordings were obtained from intercostal 
muscles near the neurological level of injury on both sides of the midline. Two clinicians 
independently counted and marked intercostal spaces along the sternum and laterally along the costal 
margin. In paper I, an indicator was placed during MRI examination to validate the true intercostal 
space. This was not performed in study IV because after testing in study I, manual counting was 
found to be reliable. The EMG recordings were obtained in rest, during voluntary activation through 
head lift and spastic activation of lower limbs.  
To avoid the influence of the pectoralis major and serratus anterior muscles, needle placement 
was selected along the edge of the sternum and along the costal margin. We also let the subjects 
specifically activate the pectoralis major and serratus anterior muscles to evaluate their signal in each 
needle position. 
As part of the screening procedure in study IV, to investigate any residual subclinical function, 
we evaluated motor-evoked potentials in the lower limbs elicited by transcranial magnetic 
stimulation of the motor cortex. Sensory-evoked potentials were also investigated by electrical 
stimulation of the lower limbs and registration with surface electrodes on the scalp overlying the 
sensory cortex. 
During surgery in paper IV, monopolar recording needles were placed in each intercostal space 
approximately two segments above and below the neurological level of injury, with reference 
electrodes in the same intercostal space approximately two centimeters laterally. Using these 
electrodes, transcranial MEP was recorded in the intercostal spaces, in addition to direct stimulations 
on the ventral roots during surgery as well as dorsal roots to elicit an H-reflex. 
Clinical imaging 
In papers I and IV, magnetic resonance imaging (MRI) was performed on all study subjects to 
investigate the anatomy of the spinal cord injury area. Since all included subjects had been operated 
on with spinal fixation at the time of their spinal cord injury, normal MRI sequences were unusable 
in the injury area because of metal artifacts. During the data collection of paper I, we found a protocol 
that was less prone to metal artifacts. The imaging was performed on a 1.5-tesla whole-body MRI 
scanner (Philips Intera Master, Best, The Netherlands) with a 15 ch spine coil (Medical Advances, 
Milwaukee, WI, USA). The diagnostic imaging protocol was acquired in a sagittal plane using a 
customized 3D TSE T2W isotropic voxel pulse sequence. The voxel size was 1.0x1.0x1.0 mm with the 
following parameters: repetition time 2000 ms, echo time 120 ms, flip angle 90 degrees, and field of 
view 300 mm. 
In study IV, functional MRI during sensory stimulation of the lower limbs is performed during 
screening to investigate potential residual subclinical function. Imaging was performed on a clinical 
3 Tesla Discovery 750w with an 8HRBRAIN-coil (GE Healthcare, Waukesha, USA). Images of the 
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cortex were acquired in a 2D coronal sequence with the following parameters: 41 slices in 128 time 
points, field of view 240x240 mm, slice thickness 3.6 mm, repetition time 2500 ms, echo time 30 ms, 
and flip angle 90 degrees. 
In paper IV, subjects operated on in Part A of the clinical trial underwent postoperative CT 
scans at 1, 14, and 60 days after surgery in the region of the SCI device to study possible adverse events 
and the degree of resorption of the device. Images were acquired on Discovery CT750 (GE 
Healthcare, Waukesha, USA) at 120 kV in helical mode and reconstructed with slice thickness 0.625 
mm, slice spacing 0.325 mm, field of view 150x150 mm, and 512x512 voxels per slice.  
Interpretation of clinical imaging 
The length of the discontinuity of the spinal cord was determined by cranio-caudal examination of 
the spinal cord in the transverse plane. The cranial marker was set where signs of neural tissue and 
exiting spinal nerves disappeared, and the caudal marker was set where these signs reappeared. 
In paper IV, the CT scans from different time-points postoperatively were co-registered for 
each study subject with three degrees of freedom (XYZ) using anatomical landmarks in FIJI (212). 
Thereafter, a cylindrical region of interest (ROI) was placed around the device in the first post-
operative image (one day after surgery), and the intensity values of each voxel in the ROI were 
exported to a .csv file. The same ROI was applied to all co-registered images from the same subject, 
and the voxels for each time-point were exported. The raw voxel data were plotted as histograms of 
the different time-points. 
Data Monitoring Committee 
The study is monitored by an independent Data-Monitoring Committee (DMC) with continuous 
access to Serious Adverse Events (SAEs) and further information at their request. The Data-
Monitoring Committee consists of two physicians (one neurosurgeon and one neurologist) and a 
statistician. The DMC is independent from the clinical trial and the sponsor of the clinical trial, 
BioArctic AB, except in their role as members of the DMC. The DMC is also tasked with the duty 
of performing interim analyses at three pre-defined points during the clinical trial and evaluating 
safety and tolerability as stated in the Clinical Study Protocol (CSP). The members of the DMC also 
function as the eligibility committee as described below. 
Eligibility committee and final inclusion 
If screening confirms a potential subject to be included in the clinical trial, all screening information 
is sent de-identified to the eligibility committee for independent review. The eligibility committee 
then gives a recommendation whether to include the patient. After screening, subjects are once again 
informed of potential adverse effects of the study procedure and offered participation in the clinical 
trial. 
Key inclusion criteria are:  
1. Traumatic Spinal Cord Injury. 
2. Male or female subjects aged between 18 and 65 years. 
3. Complete SCI (ASIA Impairment Scale level A, no voluntary bladder function, negative 
motor and sensory evoked potentials). 
4. A single spinal cord lesion injury at the neurologic level between T2-T11. 
5. A Baseline MRI that indicates a pathology consistent with a traumatic SCI 
6. Minimum of 4 months and maximum 10 years post injury with no evidence of 
neurological improvement prior to implantation surgery unless there is a complete 
anatomical cut-off of the spinal cord. 
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Key exclusion criteria are: 
1. Other life-threatening injury. 
2. Serious co-existing medical condition or mental disorder. 
3. Results from neurophysiological examination preoperatively are inconsistent with a spinal 
cord injury of one thoracic segment or less. 
Study design and randomization 
After inclusion in the study, subjects are randomized to receive either surgery and rehabilitation or 
rehabilitation only. The ongoing study is designed to include a total of 27 subjects in three parts. A 
weighted block-randomization protocol is used, resulting in six subjects randomized to surgery and 
rehabilitation and three subjects randomized to rehabilitation only for each part. Subjects 
randomized to surgery are operated on in a staggered fashion, allowing at least one month between 
surgeries to identify potential adverse events in the follow-up period before making the decision to 
operate on the next subject. 
According to protocol, subjects randomized to rehabilitation only will be offered surgery and 
rehabilitation after completion of the first rehabilitation period of 18 months, provided that efficacy 
of the treatment has been shown in the study. 
Surgery 
The surgeries of the six subjects operated on in Part A of the ongoing clinical trial presented in paper 
IV were performed at the department of Neurosurgery, Karolinska University Hospital, Solna. 
Subjects are admitted the day before surgery, and the immediate preoperative workup includes vital 
stats, blood samples, pregnancy test (in the case of a female subject of child-bearing age), and anti-
FGF1 antibodies. After all relevant clinical information is gathered, the final decision to perform 
surgery is made by the principal investigator. 
In the ongoing trial, after general anesthesia, subjects are placed in the prone position. The 
injured thoracic spinal cord is exposed, and the exact demarcation of the injury is determined through 
visual inspection in the operating microscope together with electrical stimulation of the exposed 
spinal nerves and measurements of EMG in intercostal muscles. The ventral roots are stimulated to 
verify the spinal cord segmental level and for final evaluation of the secondary motor neuron pool in 
the ventral horn, the dorsal roots are stimulated, and the intercostal EMG is monitored for reflex 
activation. An intact reflex upon dorsal root stimulation is considered indicative of a functioning 
spinal cord segment. If the injury is confirmed to be suitable for implantation (i.e. in accordance with 
the preoperative workup and of suitable length), the injured spinal cord is transected, and the glial 
scar is removed. The exact dimensions of the transected surfaces of the spinal cord are measured with 
custom-made instrumentation to find the best-fitting device from a set of 60 devices (10 different 
sizes and shapes and six different lengths, paper III). The device chosen for implantation is soaked in 
human recombinant fibroblast growth factor 1 for 60 minutes. During soaking, one of the subject’s 
sural nerves is dissected, and a portion of it is removed. The nerve is separated in fascicles suitable to 
match the dimensions of the different channels of the device; when soaking is finished, the fascicles 
are placed in the guiding channels of the device. After loading with autologous peripheral nerve 
grafts, the guiding device is placed in the resection gap between the two transected ends of the spinal 
cord and secured with sutures to the anterior aspect of the dura. A duraplasty is then performed to 
allow optimal circulation of cerebrospinal fluid around the device and spinal cord, and the wound is 
closed in anatomical layers. To ensure required air cleanliness (ultraclean air) and decrease the risk of 
contamination by airborne bacteria, mobile laminar airflow units (Toul Meditech, Sweden) are used 
to protect instruments and wound areas throughout the procedure (213). 
  41 
After surgery, subjects are transferred to the neurointensive care unit and, when stabilized, 
transferred to a standard neurosurgical ward. Length of hospitalization is individualized according 
to the medical needs of the subject. At discharge, subjects are transferred to the rehabilitation center. 
Rehabilitation and follow-up 
All included subjects, regardless of randomization to surgery and rehabilitation or rehabilitation 
only, receive specific robotic-assisted body weight-supported treadmill training in the Lokomat® 
system (56) three times a week for 18 months and an optional extension of 12 months of training. All 
follow-up visits are carried out at the rehabilitation center and include regular safety monitoring at 
planned appointments with a study physician. A follow-up visit 12 months after study completion 
has been added for all patients in the active arm. 
Reporting of Adverse Events and Serious Adverse Events 
Reporting and registration of adverse events (AEs) started the day of signing the informed consent 
for participating in the clinical trial. Any untoward medical occurrence, unintended disease or injury, 
or untoward sign (including an abnormal laboratory finding) in subjects is considered an AE, 
regardless of relation to the study intervention. An AE is considered a serious adverse event (SAE) if 
it fulfills any of the following: 
 
• results in death 
• results in a life-threatening illness 
• requires in-patient hospitalization or prolongs an existing hospitalization. To fulfill this  
criterion, the patient is to be admitted to in-patient care for medical reasons 
• results in persistent or significant disability/incapacity or impairment of body structures 
• is a congenital anomaly/birth defect (in the child of a subject who is participating in the study 
• results in medical or surgical intervention to prevent life-threatening illness or injury 
• results in fever (>39ºC) during the first postoperative month 
• is another important medical event or significant medical condition that may not fulfill  
the above seriousness criteria. This includes also medically significant laboratory abnormalities 
with or without symptoms 
 
In this preliminary report from an ongoing clinical trial, all data will be reported up to 60 days 
after surgery or inclusion with the exception of SAEs, for which all available data will be reported (i.e. 
any subject experiencing an SAE after the 60-day period detailed in this report will be also be reported 
as an SAE). 
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CONSTRUCTION OF A MICROSCOPE FROM A MICROARRAY SCANNER 
Experimental animals 
Animals were kept in enriched cages with free access to water and food in a room with a 12:12h light 
cycle. All experimental procedures were approved by the local ethics committee for animal 
experiments in Stockholm (ethical permit number 14274-2017 and N104/14).  
Hypoglossal nerve injury was induced in one adult Sprague-Dawley rat (body weight 210 g). 
The rat was anesthetized using medetomidin 0.5 mg/kg (Domitor ® Vet., Orion Pharma Animal 
Health, 1 mg/ml) and ketamine 75 mg/kg (Ketador vet., Salfarm Scandinavia, 100 mg/ml). Sodium 
chloride was administrated s.c. preoperatively and postoperatively to compensate for dehydration 
due to surgery. Using a hair trimmer (Aesculap, ISIS 273278), the fur covering the front of the neck 
was removed. The skin and muscles were incised and separated using a scalpel to expose the 
hypoglossal nerve on the right side. The nerve was avulsed using small forceps, and the skin was 
closed using running sutures (Vicryl, 4.0). 
Seven days following injury, the rat was administrated a lethal dose of pentobarbitalnatrium 
(300 mg/kg). Using a peristaltic pump (Watson Marlow, 120S), the rat was first perfused with normal 
saline (4°C) followed by 4% PFA. A second, uninjured rat was also sacrificed. The spinal cords and 
brainstems were carefully dissected and post-fixated in 4% PFA at 4°C overnight. 
Tissue clearing and staining 
The perfused and post-fixed tissue was sectioned on a vibratome (752M 152 Vibroslice, Campden 
Instruments, UK) in 0.5-1 mm thick slices. The tissue was optically cleared using a modified passive 
CLARITY protocol (11). Briefly, sections were placed in 4% acrylamide (A3553, Sigma Aldrich, 
Germany) overnight (12h). Tissue specimens were then degassed using a vacuum pump to evacuate 
the air in an air-tight chamber. Thereafter, the chamber was filled with nitrogen. When pressure in 
the chamber corresponded to the ambient pressure, the lid was opened, and the tubes were quickly 
closed. Polymerization was induced by incubation at 37°C for three hours. The sections were washed 
for a week in 8% sodium dodecyl sulfate (SDS) (L3771, Sigma Aldrich, Germany).  
The section of the brainstem was stained for 48 hours with the primary antibody Iba1-rabbit. 
After three rinse cycles in PBS with 3% Triton X-100 (X100, Sigma Aldrich, Germany) for 15 min 
each, the specimen was incubated in the secondary antibody and the cell nuclei stain for propidium 
iodide for another 48 hours and then washed again in PBS. 
For imaging, Refractive Index Matching Solution (RIMS) was prepared using 40 g of 
Histodenz (D2158, Sigma Aldrich, Germany) mixed in 30 ml of 0.02 M phosphate buffer (in-house) 
with 0.1% Tween-20 (P1379, Sigma Aldrich, Germany) and 0.01% sodium azide (S2002, Sigma 
Aldrich, Germany). The pH was adjusted to 7.5 with NaOH (S8045, Sigma Aldrich, Germany). This 
resulted in a final concentration of 88% w/v Histodenz. Tissue specimens were incubated for 12h in 
RIMS before imaging (214). 
Parts and outline of the light-sheet fluorescence microscope 
A light-sheet fluorescence microscope (LSFM) was constructed through modification of an HP 
Agilent micro-array scanner GeneArray G2500A. The optical path forming the focused laser beam 
originated from the scanner itself. In the scanner, all parts were installed on a metric optical 
breadboard (Model no 78-25555-01, Technical manufacturing Corporation, USA) measuring 38 x 48 
cm. The 0.62 mm collimated beam from a 10 mW argon-ion laser (2211-10SLHP, JDS Uniphase, 
USA), wavelength 488 nm, was expanded using a 10x beam expander (Rodenstock, Germany), 
reflected on a galvo-scanner mirror (model 6860*231, Cambridge Technology, USA), and focused 
using a f=50 mm Theta lens (Rodenstock, Germany). 
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Controlling the laser and galvo-scanner 
The argon-ion laser of the scanner could be started by shorting two wires of the control cable 
(completing the interlock-circuit, pins 1 and 3) and applying 5 volts of direct current to another cable 
(pin 2). Thereafter, laser intensity could be controlled by varying the resistance between a third pair 
of wires between 0 and 1000 ohms (pins 7 and 11). 
Through a small modification of the scanner logic board by shorting a pin on one IC by 
clamping with a crocodile clip, the amplifier circuit for controlling the galvo-scanner could be 
controlled with an external function generator (model UTG9003A, UNI-T, China). The galvo-
scanner was driven with a 200 Hz sinus wave: amplitude controlled the height of the light-sheet in 
the Y-axis, and voltage offset controlled the position of the light-sheet in the Y-axis. 
The focused and scanned beam formed the light-sheet that passed through a 170 µm thick 
microscopic cover-glass into a custom-made chamber, equipped with a NA0.3, 10x water immersion 
objective (Olympus, Japan) and situated perpendicular to the excitation axis. The image projected at 
infinity from the detection objective was passed through a StopLine® quad-notch filter (Semrock, 
USA) and collected with a 200 mm f/4 lens (Nikon, Japan) mounted on an EOS 6D DSLR (Canon, 
Japan). The tissue was mounted between two cover glasses (Marienfeld, 010243), glued to a 1 mm 
thick glass slide (VWR, SuperFrost® Plus, 48311-703), and mounted at a 45-degree angle to the light-
sheet and detection axis. Moving of the tissue was accomplished using a motorized 
micromanipulator (Model 5171, Eppendorf, USA). The joystick of the motorized micromanipulator 
was controlled with an attached manual micromanipulator (Model M33, World Precision 
Instruments, USA) with 0.1 mm resolution. This was done to enable precise control of the 
translation speed of the specimen during imaging by setting and maintaining an exact angle of the 
control joystick. 
Focal spot size 
To calculate the ideal 1/e2 width of the focused laser beam forming the light-sheet, we used the 
formula 2" = $%&' ( $)*', where l is wavelength, f is focal length of the focusing lens, and d is beam 
diameter at the lens aperture. This was compared to actual measurements made in the microscope of 
the focused laser without scanning the focal spot in the Y-axis. 
Imaging  
The custom-made imaging chamber was loaded with freshly prepared RIMS (214). In order to reduce 
the occurrence of light-scattering bubbles, the chamber was filled ~30 min prior to imaging. To 
enable recording of 14-bit raw sensor data in video mode, the open-source add-on software Magic 
Lantern© was installed on the camera using a 64GB 1000x CompactFlash® (Komputerbay 
Professional). The continuously acquired images were temporarily stored on the same flash card 
during imaging and then converted to cinemaDNG-sequences using the software RawMagic 1.0. 
Resolution, sensitivity of the image sensor (ISO-number), and frame rate were chosen based on the 
specific imaging conditions.  
Specimen Z-translation 
To enable acquisition of isotropic voxels through an image stack, movement in the Z-axis during 
imaging must match the lateral resolution multiplied by the frame rate. Because we used a 
micromanipulator with a joystick interface, the relation between joystick angle and Z-axis speed had 
to be determined empirically. We used a 1D micromanipulator with 0.1 mm resolution attached to 
the joystick to set a specific joystick angle and recorded images of a Bürker Chamber Glass slide with 
a printed square pattern (Heinz-Herenz, Hamburg, Germany) translated along the Z-axis of the 
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microscope. We then calculated the mismatch in lateral and Z-axis resolution using FIJI (212) for a 
number of different joystick angles. The results obtained were fitted to a third-degree polynomial 
function using R (206), and an interactive interface was created using Shiny (215) to obtain the correct 
settings quickly during imaging (https://frostell.shinyapps.io/speedSetting). 
Image processing  
Raw sensor data acquired with Magic Lantern were converted to the CinemaDNG format using 
Raw Magic 1.0. Bayer interpolation was applied in DaVinci Resolve Lite (Blackmagic Design, USA). 
Images were exported from DaVinci as 16-bit TIFF images and imported into ImageJ. Using a 
custom-written macro, the images were converted (resliced) from being orthogonal to being 
longitudinal in relation to the tissue. In the final step, the images were shifted (translated) in order to 
realign the images and reconstruct the original shape of the tissue. Specifically, prior to translation, 
the images formed a representation of the tissue resembling a parallelogram. Translation restored the 
rectangular shape of the tissue by shifting the intermutual relation between the images. A Mac Pro 
with a 3 GHz 8-core Intel Xenon E5 processor was used for image processing. The workstation was 
equipped with 64 GB 1866 MHz DDR3 ECC memory and an AMD FirePro D500 3072 MB 
graphics cards. 
Automatic cell counting 
Cell nuclei overlapping the primary antibody staining (Iba1) were counted automatically using FIJI 
(212). Specifically, we first applied a region of interest around the hypoglossal nuclei, multiplied voxel 
values from the red channel (representing cell nuclei) by voxel values from the green channel 
(representing Iba1 positive cells), and then applied a threshold and counted the cells with the 3D 
simple segmentation tool in FIJI (212). Data on the XYZ position of each identified cell were exported 
as a .csv file and imported in R (206) for plotting. Data presentation was conducted using packages 
ggplot2, cowplot, and shiny (215). 
Cost-estimation of the microscope 
Because most of the parts used in the microscope were already in our lab when we started the 
construction, our estimation of the costs of the parts represents a best-guess based on what we 
considered an average price on common markets for used laboratory equipment (e.g. ebay.com). 
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RESULTS 
 
The papers in this thesis describe parts of the translational process of a preclinical regeneration 
strategy for complete chronic thoracic spinal cord injury to a clinical trial (papers I-III), the short-
term safety reported in the ongoing clinical trial “Safety and Efficacy of SC0806 (Fibroblast Growth 
Factor 1 and a Device) in Traumatic Spinal Cord Injury Subjects” (paper IV), as well as the 
construction of a low-cost light-sheet microscope (paper V). 
PAPER I – INTERCOSTAL EMG PRECISELY DEMARCATES A THORACIC SCI 
Five male patients with complete chronic SCI in the thoracic cord were included. Written and 
informed consent was acquired from all subjects. Age of patients were 32-50 years (median 35), 1-4 
years post injury (median 3). Three patients were injured in motorcycle accidents, one patient in a 
motor vehicle accident and one in an accident with a hang-glider. All patients presented as AISA A 
and remained so throughout the clinical course. None of the patients had a clinical history of 
frequent autonomic dysreflexia. 
Clinical examination 
Patients underwent clinical examination to confirm that all inclusion criteria were met. They were 
all determined ASIA A as their clinical history suggested. Neurological level was T3-T6 (median T5) 
and lower body spasticity was present in all patients. 
Neurophysiology 
To assess motor function of the thoracic spinal cord bipolar needle EMG registrations in the 
intercostal muscles were performed. Three distinct patterns were recognized: Above the level of SCI 
normal, voluntarily activated motor unit potentials (MUPs) appeared . At, or close to, the level of 
sensory loss patients presented a varying number of intercostal spaces with spontaneous EMG 
activity with fibrillation potentials and positive sharp waves. Below the level of injury there were once 
again normal MUPs, generated in concert with spastic activation of lower limbs. The registrations 
and number of denervated segments from the five individual patients are presented in paper I.  
The patients’ sensation of the needle insertion was used to determine the sensory level. It was 
coherent with motor level in two patients, was found one segment above voluntary motor level in 
two patients, and one segment below motor level in one patient. 
MRI 
MRI was performed in all patients to give an anatomical overview of the individual injury and 
facilitate interpretation of results from neurophysiology. In this sample of five ASIA A thoracic SCI 
patients the anatomical extent of the SCI varied. The length of spinal cord discontinuity was 13–60 
mm, with the median found at 30 mm. All patients had their spine previously internally stabilized 
with titanium instrumentation. 
Comparing Neurophysiology and MRI 
The number of denervated segments was plotted against the length of the spinal cord discontinuity 
as judged by MRI. The Pearson product-moment correlation coefficient for no of denervated 
segments and length of lesion was r = 0.97, p < 0.01. 
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PAPER II – SEGMENTAL DIAMETERS OF THE HUMAN SPINAL CORD 
Published measurements can be combined by adjusting craniocaudal position 
To estimate the effect of the adjustment of craniocaudal position of measurements, we set up 
two second-degree polynomial regression models. The R-squared value for Model 1 (uncorrected 
positioning) was 68.8% and 86.4% for Model 2 (corrected positioning), which was applied to the 
corrected data. The 95% confidence intervals for the R-squared values were non-overlapping, 
indicating a robust difference. 
All measurements combined to continuous estimates along the spinal cord 
To construct continuous population estimates and achieve further smoothing, a generalized additive 
model was fit to the weighted averages and weighted standard deviations. 
The smoothed continuous population estimates of human spinal cord transverse and 
anteroposterior diameters of the spinal cord showed the expected shape with a marked cervical 
intumescence and a smaller lumbar intumescence. The anteroposterior diameter decreased 
throughout the spinal cord. See paper II for figures and tables of the human spinal cord size. 
PAPER III – DESIGN OF A GUIDING DEVICE FOR CLINICAL TRIAL 
Simulated segmental spinal cord sizes 
Two hundred matched spinal cord transverse and anteroposterior diameters was simulated for each 
segmental level of the human spinal cord based on data from paper II. Varying the correlation of the 
bivariate distribution for each segmental level (from higher correlation in the lumbar spine to lower 
correlation in the cervical spine) allowed the simulated data to satisfy not only the targeted 
distribution of transverse and anteroposterior diameters but also the shape constraint observed in 
raw data from measurements of real patients (i.e. regardless of variations in size, the cross-section of 
the spinal cord can never be too “round” nor too “flat”). From the results obtained, the variation 
between segments of the spinal cord’s elliptical shape and size was much smaller in the thoracic cord 
compared to the cervical and lumbar portions of the spinal cord. 
Error between the simulated thoracic spinal cord and guiding devices 
The chosen set of seven guiding device sizes was compared to the simulated thoracic segments T2–
T12. For each simulated thoracic segment, we calculated the Euclidian distance to the guiding device 
sizes to find the device that best fit a given simulated thoracic spinal cord segment.The guiding device 
size termed “normal 1” was the most frequent “best fit,” reflecting its centered position over the 
distribution of thoracic spinal cord sizes and the design choice to focus on having enough head-room 
to handle intraoperative swelling of the spinal cord due to manipulation. 
The mean error-of-fit comparing simulated spinal cord segments T2–T12 to the best elliptical 
shape was 0.41 mm and 0.36 mm, the median was 0.31 mm and 0.31 mm, and the 95th percentile was 
found at 1.3 mm and 0.98 mm for transverse and anteroposterior diameter, respectively. The mean, 
median, and 95th percentile of the Euclidian distance was 0.60, 0.48, and 1.63 respectively. The mean 
and median area mismatch was 14.23 mm2 and 10.93 mm2 respectively, and the 95th percentile was 
found at 41.40 mm2. 
The vector model of the human thoracic spinal cord 
The variations in white-to-grey matter delineation in segments T2 to T12 were small both within 
subjects and between subjects. The angle of the dorsal horn increased in the cranial direction in both 
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subjects, and the transverse distance between the anterior grey matter on each side was slightly 
different between subjects. 
The spinal cord interfaces and graft channels of the guiding device 
Using the vector model of the human thoracic spinal cord, we designed a set of channels connecting 
the 2 spinal cord interfaces with each other for placement of the autologous peripheral nerve grafts. 
A device design was reached for capturing the majority of corticospinal axons at the cranial interface 
of the device and guiding them obliquely to grey matter at the caudal interface.  
The alignment of guiding device channels and spinal cord white matter tracts 
By comparing the white-to-grey matter delineation from the vector model scaled to the sizes of the 
simulated spinal cord segments and overlaid with the best-fitting device size, we made a qualitative 
assessment of the alignment between the guiding device channels and the spinal cord white matter 
tracts. 
PAPER IV – ADVERSE EVENTS FROM AN ONGOING CLINICAL TRIAL 
Neurological Outcome During the First Two Months 
In the first six subjects operated upon, glial scar resection and implantation could be performed 
without deterioration of neurological function as determined by neurological examination. No 
significant autonomic changes were seen except a transient increase in sweating in some subjects. 
Perioperative morbidity had a profile that could be expected considering that the trial includes a 
surgical intervention in a vulnerable patient group. The adverse events (AEs) outside the expected 
possible complications to surgery were postoperative aseptic meningitis after one week in two 
subjects and markedly reduced spasticity in one subject, both AEs are detailed further below. The 
short-term safety and tolerability merits continuation of the study, and the results obtained indicate 
that provided the use of precise preoperative and intraoperative monitoring, glial scar resection and 
implantation can be performed in a selected patient group without deterioration of neurology. 
Eligibility and Inclusion 
During recruitment to Part A, 22 potential subjects were screened for eligibility. Three subjects were 
excluded during pre-screening due to unstable mental health (one subject), complex and 
asymmetrical spinal cord injury (one subject), and lack of consent (one subject). The remaining 19 
subjects went through the screening process at Karolinska University Hospital. Ten subjects were 
excluded during the screening phase due to injury longer than one thoracic spinal cord segment (five 
subjects), complex and asymmetric spinal cord injury (two subjects), and withdrawal of consent 
(three subjects). 
The remaining nine subjects were randomized to receive either surgery and rehabilitation (six 
subjects) or rehabilitation only (three subjects). Follow-up and rehabilitation are ongoing and have 
not been finalized for Part A. 
Neurophysiology and imaging during screening 
None of the subjects screened in Part A had any remaining voluntary function below the injury level 
as determined with EMG, transcranial MEP, and transcranial SEP. None of the subjects who 
underwent functional MRI demonstrated any signs of residual function. 
The intercostal EMG in the injury area distinguished several different patterns. Above the 
injury, we found normal, voluntary activated motor unit potentials (MUPs). Near the sensory level 
of the subject, voluntary MUPs disappeared in some subjects above the sensory level, and in some 
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below. Well below the sensory level, we found MUPs of normal configuration that were not 
voluntary activated. Instead, these MUPs were activated in concert with spastic activation of the 
lower limbs of the subject. Near the sensory level, subjects had segments showing signs of denervation 
with fibrillation potentials and positive sharp waves (indicating a previous axonal nerve injury) as 
well as signs of re-innervation after peripheral nerve injury with large-amplitude neurogenic MUPs. 
Some subjects also had completely silent segments in the injury area. Some subjects (5/15) who 
underwent intercostal EMG were found to have an injury spanning more than one neurological 
segment and were therefore excluded. 
Study Population 
Of the nine subjects included in Part A, there were seven males and two females. All subjects 
randomized to surgery were male. Injury mechanisms in the subjects were motor vehicle accident 
(n=4), fall (n=3), parachute accident (n=1), and motor-cross accident (n=1). In the surgery group, 
subjects’ ages were 25-56 years (median 30). Surgery was performed at 14-42 months after injury 
(median 27.5 months). In the control group, injury mechanisms were fall (n=2) and motor vehicle 
accident (n=1), age was 33-48 years (median 36), and inclusion in the study was 35-57 months after 
injury (median 46). See table 1 for a summary of the included subjects’ demographic characteristics. 
Surgery 
No AEs were reported during surgery. Intraoperative neurophysiology confirmed findings from the 
preoperative neurophysiology and was used to guide resection margins of the glial scar. In all subjects, 
the glial scar was resected to expose what visually appeared as viable spinal cord both above and below 
the glial scar. The lengths of the devices implanted in the first six subjects were 15, 25, 30, 35, 40, and 
40 mm. Median surgical time was 8 h and 51 min (7 h 18 min – 10 h 20 min). 
Neurological level was not affected by glial scar resection and implantation 
As determined by neurological examination, none of the subjects had a deterioration of neurological 
function above the complete thoracic spinal cord injury after the surgery with glial scar resection and 
implantation of device. Sensory levels stayed unchanged during the current reporting period from 
surgery to complete degradation of the device at 60 days post-surgery. 
Serious Adverse Events (SAEs) 
No SAEs were encountered during surgery, and no SAEs were encountered during rehabilitation. 
However, during the first post-operative month, five SAEs were reported in three of the six operated 
subjects. The SAEs encountered in the operated subjects were as follows: pneumonia, Clostridium 
difficile enterocolitis, two cases of postoperative fever (>39.5°C), headache and elevated white blood 
cell count in CSF, and one case of hygroma. All five SAEs were considered possibly related to the 
study procedure, and all five SAEs resolved with no lasting effects on the subjects in whom they 
presented. One subject in the surgery group had a urological SAE after inclusion but five months 
before surgery. This SAE was considered unrelated to the study.  
One of the subjects randomized to rehabilitation had four SAEs during the follow-up period: 
rib fracture, pyelonephritis, and two undisclosed SAEs that led to early withdrawal from the study. 
All four SAEs in the control group were considered not related to the study. See table 2 for a 
comparison of SAEs between groups. 
Length of stay after glial scar resection and implantation of device 
Subjects spent 3.5 days on average in the neurointensive care unit (NICU) after surgery for 
monitoring (range 3-4 days) and were discharged to the rehabilitation clinic after 17 days on average 
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(range 13-20 days). One subject was readmitted to the NICU during the inpatient period for two days 
because of fever and headache, and one subject was readmitted to the hospital after discharge due to 
hygroma. 
Glial scar resection and implantation of device resulted in transient, aseptic fever 
and headache one week postoperatively in some subjects 
Two SAEs in two subjects were related to postoperative fever (>39.5°C), headache, and elevated white 
blood cell count in CSF. Three of the remaining four subjects also reported slight headache, 
photophobia, and elevation of body temperature for one or two days, starting about one week 
postoperatively. The two subjects with more pronounced fever and headache underwent lumbar 
puncture at two occasions each. Testing showed increased white blood cell count in CSF, but no 
pathogens were found in cultures or using broad-range PCR/ESI-MS (216). The subject suffering 
from hygroma had underwent two lumbar punctures. Whether the reason for the hygroma was due 
to the surgery and implantation or due to repeated lumbar punctures is unknown. 
Neurogenic pain decreased after glial scar resection and implantation of device 
Three out of six subjects had significant neurogenic pain in the zone of partial preservation before 
surgery. This pain was immediately relieved after the operation, enabling one of the subjects to quit 
his pain medication with Pregabalin. During the first 60 days, some of the pain returned but was 
greatly reduced, and no additional pain medication was needed. 
Spasticity increased in one subject and decreased markedly in one subject after glial 
scar resection and implantation of device 
One subject reported increased spasticity after surgery and had to start medication with oral Baclofen 
and Mirabegron to alleviate spasticity and problems with neurogenic bladder. In one subject, 
spasticity reduced markedly after glial scar resection and implantation of the device and resulted in a 
flaccid paresis below the level of injury. Oral Baclofen was discontinued. 
Ongoing and Possibly Related AEs at 60 days postoperatively 
At 60 days postoperatively, there were eight ongoing and possibly related AEs in four subjects. Three 
subjects experienced increased sweating near or below the neurological level but with continuously 
decreasing intensity. One subject started an SSRI for depressive symptoms 3 weeks after surgery. At 
60 days postoperatively, the symptoms were relieved, but the subject was planned for continued 
medication for the recommended 6 months. Two AEs were related to significantly decreased 
spasticity in one subject developing within the first month after surgery with a decrease in reflex 
erection, and another was related to increased spasticity in another subject. The last ongoing and 
possibly related AE was reported in a subject where neurogenic pain in the zone of partial 
preservation (ZPP) had diminished markedly after surgery. After a couple of weeks, the subject 
experienced a return of some neurogenic pain near the ZPP, albeit at a lower level than before 
surgery; this was still reported as an AE. 
Guiding Device was Completely Resorbed during the First Two Months 
CT scans of the device area showed a rapid degradation of the device. At 14 days after surgery, the 
device showed signs of degradation in all subjects. At 60 days, the device had disappeared in six out 
of six subjects. In the quantitative image analysis, a peak of high attenuating voxels was seen at around 
1500 Hounsfield Units representing the calcium sulphate guiding device material. This peak 
diminished at 14 days and was completely abolished at 60 days after surgery in all subjects, indicating 
complete degradation of the guiding device. 
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PAPER V – A LOW-COST LIGHT-SHEET FLUORESCENCE MICROSCOPE 
Only minor modifications to the microarray scanner were needed to create the 
light-sheet 
The laser of the microarray scanner could be started and controlled with minor modifications to the 
control cable. The galvo-scanner could also be controlled by shorting one IC and inserting a control 
signal to the logic board of the microarray scanner with a function generator. These two minor 
modifications enabled the formation of a scanned light-sheet at a fraction of the cost for similar 
optical parts. Constructing the detection axis of the microscope required more effort because a 
custom-made imaging chamber was needed to enable immersed imaging. Further, the microscope 
objective, fluorescence filter, tube lens, and camera had to be added to the scanner. Fortunately, 
several circular lens holders and a micromanipulator were among the unused parts from the scanner 
itself after modification and could be used to stabilize and position the detection axis. 
Light-sheet dimensions were wider than predicted 
The empirical full-width at half maximum of the laser focal spot was 5.3 µm, and the corresponding 
1/e2 width was 9 µm. The expected 1/e2 width from an ideal system with the characteristics defined 
is 5 µm, and the full-width at half maximum is 2.9 µm. 
Estimated cost of the microscope was about one tenth of OpenSPIM 
We estimate the cost of our microscope to be USD 6,000. For comparison, one recent realization of 
the OpenSPIM architecture cost about USD 60,000 (27). About half of that cost was for laser and 
optical components, which could be sourced from the microarray scanner at about USD 1,000. 
Because most of the parts used in the microscope were already in our lab when we started the 
construction, our estimate of the cost represents a best-guess based on our searching of sources of 
used laboratory equipment such as ebay.com. Additionally, depending on location, transportation 
can be a major part of the cost for the microarray scanner. We bought a used scanner from North 
America on eBay. The cost of the instrument was USD 200, but total cost including transportation 
was USD 1,000. 
Hypoglossal avulsion injury resulted in a significant proliferation of Iba1+ cells in 
the hypoglossal nuclei one week following injury 
We applied our microscope to a hypoglossal nerve injury model employed in our lab and quantified 
the increase in immunoreactivity for Iba1 one week after injury. The automatic quantification of 
images collected using the LSFM showed an approximate doubling of Iba1-positive cells and could 
be visualized in three dimensions thanks to the optical sectioning and en bloc imaging. The image 
acquisition time for the entire hypoglossal nuclei on both sides in a rat was about 4 minutes for 
collecting 5000 frames at 2 MP or ~10 billion voxels. The high-speed imaging possible with light-
sheet fluorescence microscopy makes quantifications of large tissue volumes possible.  
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DISCUSSION 
 
The papers in this thesis describe parts of the translational process of a preclinical regeneration 
strategy for complete chronic thoracic spinal cord injury to a clinical trial (papers I-III), the short-
term safety reported in the ongoing clinical trial “Safety and Efficacy of SC0806 (Fibroblast Growth 
Factor 1 and a Device) in Traumatic Spinal Cord Injury Subjects” (paper IV), as well as the 
construction of a low-cost light-sheet microscope (paper V). 
EVALUATING THORACIC MOTOR FUNCTION WITH INTERCOSTAL EMG 
In paper I, we report that electromyogram (EMG) of the intercostal muscles could be used in thoracic 
SCI to establish the cranial and caudal margins of motor neuron function. This method was also used 
in paper IV, which confirmed the applicability of the method in a larger study group and its 
usefulness in evaluating patients for eligibility in a clinical trial involving patients with thoracic spinal 
cord injury. Neither paper I nor paper IV has found any adverse effects of the method other than 
local pain from the EMG needle. Spastic activation of motor-evoked potentials a couple of segments 
below the injury has been possible in all patients investigated. In the injury zone, most study subjects 
have shown signs of denervation, and the extent of the denervation in number of segments is 
consistently in agreement with the craniocaudal extent of the spinal cord injury on MRI. It should 
be noted that the method does not discriminate between incomplete and complete injuries since it 
does not target long fiber tracts crossing the injury zone. Also, sensory and autonomic functions are 
not evaluated.  
We argue that interventional studies targeting thoracic spinal cord injury should use intercostal 
EMG to evaluate motor function precisely. When extrapolating findings from interventions in the 
thoracic spinal cord to the cervical spinal cord, it is of utmost importance to identify whether an 
intervention has a negative effect on local motor function. Theoretically, an intervention could 
improve distal functions such as movement of legs or urogenital function but still show a local 
negative effect in the injury area with loss of motor function in that specific area. If such an 
intervention was applied to a cervical injury or high thoracic injury, important hand functions might 
be lost, negating any positive distal effect seen from the treatment. The risk of such mistakes could 
be reduced by applying the method described in paper I in clinical trials involving thoracic spinal 
cord injuries. 
COMPARING STUDIES ON HUMAN SPINAL CORD CROSS-SECTIONAL SIZE 
In paper II, we gather data on segmental cross-sectional size of the normal human spinal cord from 
all available published sources and created continuous estimates along the craniocaudal axis. Various 
methods were used in these different studies, including radiological in vivo measurements and post-
mortem examinations of spinal cord size. Because different studies used diverse anatomical 
landmarks for the measurements, we created a conversion table between neuronal spinal cord 
segments and vertebral bony segments to enable convergence of the data on a common craniocaudal 
axis. We found that the conversion table aligned the cervical enlargement in a statistically superior 
way as compared to using raw segmental data to align segments. Data on the cervical spinal cord were 
more abundant, and the proportion of in vivo measurements was greater compared to the thoracic 
and lumbar spinal cord. In the sacral and lumbar spinal cord, the shape changes rapidly along the 
cranio-caudal axis. Therefore, studies using vertebral bony segments as a landmark utilize an 
insufficient sampling frequency to capture the change in size accurately in this part of the spinal cord, 
and the increase in standard deviations reported by us and others in this part of the cord should 
probably be interpreted to reflect measurement error rather than actual biological variation. To our 
 52 
knowledge, paper II is the first study that combines measurements from several published studies on 
the spinal cord within a common craniocaudal axis. Therefore, the resulting estimations in size and 
variability of the human spinal cord should be of interest to future research in which the dimensions 
of the spinal cord are of importance (e.g. interventional or diagnostic studies on spinal cord 
pathology). 
Refining and validating the conversion table between vertebral bony segments and spinal cord 
neuronal segments hold promise for future use as a radiological aid to predict the actual relationship 
between clinical neurological findings in a patient and radiological pathology in the spinal cord. A 
major hurdle to accomplishing this is that without knowledge of the exact demarcation of the injury 
in the cord, correlating findings with neurological level and validating the method are challenging. 
To overcome this hurdle, analysis of spinal cord injuries resulting from injuries like stab wounds 
where the location of the pathology can be exactly defined is a possible solution. 
One study on spinal cord size that should have been included was found after publication (217). 
Although it is unfortunate that the study was not included, the results from this study agree with the 
data generated from our meta-analysis and would not have changed means and confidence intervals 
significantly.  
DESIGNING A GUIDING DEVICE FOR TRIAL IN COMPLETE THORACIC SCI 
In paper III, we describe the design and sizing of the guiding device used in paper IV. The design was 
based on the concept of white-to-grey matter guiding shown to be effective in preclinical studies 
(170,173,174,183,184) applied to human spinal cord anatomy. The placement of guiding channels was 
based on degeneration studies and observations from highly localized injuries to the spinal cord such 
as stab injuries. Recent advances in high-field magnetic resonance imaging have produced anatomical 
images of spinal cords ex vivo with spatial resolution down to 50 um (218). The same study showed 
sufficient resolution in diffusion tract imaging and tractography to inform possible future designs. 
If in the future such high-field imaging is possible in patients despite artifacts produced by metal in 
spinal instrumentation, guiding devices could be manufactured and chosen before surgery based on 
the size and anatomy of the specific patient. At present, image quality in MRI of SCI patients cannot 
determine the exact size of the cord near the injury because of metal artefacts; we therefore chose to 
define a set of device sizes covering the probable spinal cord sizes encountered based on data from 
paper II. We used the data from paper II to simulate spinal cord sizes and reported the distributions 
of relevant measurements with the error-of-fit between our set of devices and the simulated spinal 
cords. 
We also added three larger devices to account for swelling of the spinal cord during surgery. 
Swelling of the cord was not observed in the first six operations performed in paper IV, and the 
smaller sizes of the devices have been used more often, possibly reflecting atrophy after spinal cord 
injury (219). 
The simulations presented and the approach to evaluating device sizes could be used to inform 
further research in which a direct physical interaction with the spinal cord is required such as bridging 
approaches or injection of cells. 
SAFETY ASSESSMENT AND SURGICAL METHOD IN A PIG MODEL 
An important step in the translational process not detailed in this thesis was the application of the 
clinical guiding device (paper III) loaded with FGF1 and nerve grafts in a pig model of thoracic spinal 
cord resection to establish the surgical method and evaluate short-term safety. The data were 
collected by an external monitor according to good laboratory practice. The study showed no 
unexpected adverse effects of the procedure, and results are in preparation for publication (220). 
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EARLY ADVERSE EVENTS IN THE ONGOING CLINICAL TRIAL 
After establishment of preclinical efficacy and dosing (183,184,186), refinement of clinical tools for 
patient selection and evaluation (paper I), adaption of the guiding device to human dimensions 
(paper II and III), evaluation of the surgical method and safety in a large animal model (220), and 
securing of funding and formal approval, the study “Safety and Efficacy of SC0806 (Fibroblast 
Growth Factor 1 and a Device) in Traumatic Spinal Cord Injury Subjects” was started with the 
pharmaceutical company BioArctic AB as sponsor. This randomized, rehabilitation-controlled 
phase I/IIa trial is the first clinical trial in humans investigating glial scar resection and implantation 
of a biodegradable guiding device containing peripheral nerve grafts and fibroblast growth factor 1 
(FGF1) in complete (AIS-A) thoracic spinal cord injury. 
In paper IV, we report adverse events in the first six subjects operated upon and the three 
subjects undergoing rehabilitation only serving as controls. Rehabilitation is ongoing, and the 
primary endpoint for part A has not been reached. We present adverse events during the first 60 days 
postoperatively, and to increase transparency we also describe all serious adverse events encountered 
to date (November 2018) in the study. Further, the degradation of the guiding device as judged by 
computed tomography scans are presented. 
Glial scar resection and implantation could be performed without deterioration of neurological 
function, despite the need to place the cranial resection margin into structurally normal spinal cord 
tissue. Considering that the trial includes a surgical intervention in a vulnerable patient group, the 
majority of adverse events had a profile that could be expected. The adverse events outside the 
expected possible complications to surgery were postoperative aseptic meningitis after one week in 
two subjects and markedly reduced spasticity in one subject. The cases of aseptic meningitis resolved 
without any lasting effects on the subjects.  
Interestingly, three out of six subjects who pre-operatively reported chronic neurogenic pain in 
the injury zone were all relieved of pain in the immediate (60 days postoperatively) period after 
resection of the glial scar. This suggests that the neurogenic pain in these subjects had some 
correlation to the structural changes found in a spinal cord injury. Degradation of the guiding device 
was observed to be complete at 60 days postoperatively as judged by computed tomography. 
Taken together, the short-term safety and tolerability were considered acceptable for 
continuation of the clinical trial. 
CONSTRUCTING A DIY LIGHT-SHEET FLUORESCENCE MICROSCOPE 
In paper V, we describe the construction of a low-cost but capable light-sheet fluorescence 
microscope from an outdated micro-array scanner. We applied the microscope to an experimental 
CNS-injury model used in our lab and automatically quantified the increase in microglia following 
the injury. Imaging time for capturing the relevant tissue volume at a resolution suitable for 
automatic cell counting was just a couple of minutes, demonstrating the feasibility for in toto imaging 
of all replicates in a larger experiment. The main obstacle we encountered for extended use of the 
light-sheet fluorescence microscope has been the difficulty in acquiring consistent immunostaining 
and transparency of biological tissue across different antibodies and injury types. Many biological 
questions can still be answered in a more efficient manner with two-dimensional microscopic 
techniques because it allows faster processing tissue and easier handling of data from microscope to 
publication. 
To realize the potential of light-sheet microscopy beyond beautiful images, consistent contrast 
generation and tissue transparency have to be combined and applied to unanswered biological 
questions inaccessible by traditional thin sectioning such as the complex network architecture of the 
CNS. 
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ETHICAL ASPECTS OF CLINICAL TRIALS IN SPINAL CORD INJURY 
Thanks to the improvements in care and treatments of medical problems after SCI during the 20th 
century, SCI has transformed into a non-lethal chronic condition, albeit with significant effects on 
neurological function and health-related quality of life. Therefore, in the view of the author, SCI is 
not a condition for which investigation of new invasive interventions outside the rigorous framework 
of clinical trial can be motivated.  
Clinical trials have the disadvantage of slow processes and high cost, but the process also has 
numerous important advantages. Key aspects of clinical trial design have evolved over time in 
research and health care systems to introduce new treatments in a safe and reliable manner. Informed 
consent from study subjects is a cornerstone of all clinical research, especially those involving 
interventions. Ethically sound clinical trials go to great length ensuring adequate participant 
information, rigorous documentation of the consent, as well as the possibility for the study subject 
to opt out at any time in the process. Formal approval by independent ethical committees and review 
by medical products agencies ensure that unbiased professionals review the underlying evidence for 
potential benefits and risks for study subjects. The publication of study protocols and primary 
endpoints before starting the study ensures that statistical significance in outcome measures are valid 
and not a result of datamining among many potential candidate outcomes. The use of 
randomization to intervention or control groups ensures that estimation of effect size is not due to 
differences in baseline characteristics or other effects of inclusion in a research study.  
Despite every effort to ensure safety in study subjects, many treatments tested in clinical trial 
will lack efficacy, and some will even show harm. Therefore, the utilization of structured reporting 
of adverse events and independent monitors of safety during the study are pivotal for promoting 
unbiased evaluation of adverse events and the need for early study termination. If performed in a 
rigorous manner, even failed trials can still add important information to the field and inform further 
research. 
Invasive procedures in the acute phase of SCI pose a significant challenge in regard to patient 
safety because at present no method for early evaluation of SCI patients can predict the clinical course 
with certainty. An early intervention thus poses the risk of harm to the patient beyond the initial 
injury. In the chronic phase, however, the neurological outcome of the patient is known, and any 
changes from that level of functioning, deterioration, or improvement can probable be attributed to 
the intervention. The most important ethical dilemma in the chronic stage is the physical risk that an 
intervention exposes the study subject to, as well as psychological risk in terms of hope of 
improvement. 
COMPLETENESS OF SCI IN THE ERA OF SPINAL CORD STIMULATION 
The concept of “complete” SCI according to the AIS definition is based solely on clinical neurological 
examination by a skilled health care professional observing and interviewing patients with regard to 
their conscious connection with body parts below the neurological level of injury. This definition of 
completeness is adequate and highly relevant in the rehabilitation setting because it clearly predicts 
the impact of the injury on activities of daily life. From an academic standpoint, however, this view 
of completeness has been challenged for decades, showing that some patients classified as AIS-A still 
could exert subclinical but undoubtedly voluntary modifications of movement such as spasticity or 
reflexes below the neurological level of injury (221). It was also recently shown that some AIS-A 
patients respond to sensory stimulation below the level of injury when investigated with functional 
MRI (222). As for being subclinical, the concept of “discomplete” spinal cord injury has no practical 
implications for the patient because residual function is so limited, and neither did it have 
implications for the indication for interventions such as resection of an injured spinal cord segment 
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(“cordectomy”), a procedure shown to be beneficial in a group of patients with progressing post-
traumatic syringomyelia (223). However, several recent publications on epidural electrical 
stimulation of the lumbar spinal cord (224,225) have put new light on the earlier purely academic 
question of “discomplete” SCI. When stimulating the lumbar spinal cord within a set of defined 
parameters, facilitation of voluntary function has been seen, as well as the ability for activation of 
spinal pattern generators and stepping patterns (224,225). 
In the ongoing clinical trial detailed in paper IV in this thesis, study subjects have undergone 
functional MRI and have also been investigated with motor-evoked potentials and sensory-evoked 
potentials during screening. These additional investigations of the study subjects minimize the risk 
for inclusion of a patient with subclinical residual function and a potential future benefit from 
epidural stimulation. Additionally, all meaningful recovery of function through epidural 
stimulation has so far been limited to patients with incomplete injuries as classified with neurological 
examination. Nevertheless, the results from epidural stimulation in chronic SCI clearly highlight the 
potential benefits of a regeneration strategy able to restore some axonal connection between the 
disconnected caudal spinal cord and the part of the central nervous system still under voluntary 
control. 
THE POTENTIAL OF OUTDATED SCIENTIFIC EQUIPMENT 
In a time of increasing consciousness of the negative environmental impact of human activity on our 
planet, the advantage of reusing products at the highest possible level of functioning has clear 
benefits. Even though the micro-array scanner used in paper V has played its role as a scientific 
instrument in its original design, the optical and electrical components were fully functional, and 
specifications were comparable with identical parts that can be purchased new at a much higher price 
and environmental impact. If put through the garbage-collecting system (which is often the case 
when old scientific equipment is no longer useful in the lab), the complex and ingenious micro-array 
scanner transforms into 100 kg of metal waste polluted with rare trace elements from electronic 
components, plastics, and glass. This is an unnecessary destruction of resources if components can 
be reused.  
A major hurdle to the efficient reuse of old scientific equipment is the unwillingness of 
manufacturers of equipment to publish service manuals and codes for communication and 
programing of microcontrollers in the instruments through the serial interface that is usually present. 
With this knowledge, the light-sheet microscope in paper V could have been constructed at a fraction 
of the time because reverse engineering of basic functions would not have been necessary, and most 
of the microscope could have been controlled by software without modification of the hardware. It 
is obvious that private companies need to protect their intellectual property in development and 
during commercialization of products, but in the late phase of the life-cycle of products, releasing 
detailed information about the instruments would significantly facilitate the recycling of scientific 
equipment. 
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FUTURE PERSPECTIVES 
The secondary injury ensuing after the initial trauma in SCI has been a target for intervention for a 
long time because of the feasibility-in-treatment window and the clearly positive effect found in 
countless of preclinical experimental studies. The ever-expanding knowledge of the complex biology 
underlying the fine-tuned balance between rescuing uninjured function and sacrificing regeneration 
results in new potential targets for future treatments at a high pace. When considering the diverse 
panorama of injuries encountered in the clinical setting and the multifaceted response to injury in 
the CNS, the failure to show efficacy in clinical trials in SCI over the last decades is unsurprising. The 
positive effect shown in a controlled preclinical injury leading to a clinical trial probably helped a 
subset of patients in the trials but had no effect or even showed harm in patients with a different 
injury biology. The combined result was failure to show efficacy in the primary endpoint of the trial. 
Several promising strategies including non-pharmaceutical protocols are reaching phase III at 
present (159). In combination with better diagnostic tools such as biomarkers and more advanced 
MRI, these steps indicate that some intervention will show benefit in some subset of patients in the 
near future. This would be an important milestone in the decades of preclinical and clinical work 
that so far have not resulted in any undisputed high-level evidence for any intervention in acute SCI 
except support of vital parameters and prevention of medical complications. Finding an intervention 
for acute SCI probably would not mean total return of pre-injury function in all patients, but it 
would result in a gradual shift of demographics from complete and severe injuries to an even higher 
number of incomplete injuries than what is seen today in the clinic (42). 
Although important to find treatments for secondary injury, primary prevention can often be 
less expensive and seldom receives the focus it deserves. In the elderly with weaker bone due to 
osteoporosis, it has been shown that the impact of a backward fall on the buttocks can be enough to 
sustain a burst fracture in the spine; simply lowering the stiffness of the floor or providing other low-
tech protection is enough to make this injury type unlikely (36). 
Although a further shift in demographics toward incomplete injuries is likely in the future in 
high-income regions, the long life expectancy after SCI means the shift will be slow; additionally, low 
income regions that are currently experiencing an increase in motor-vehicle transportation will most 
likely experience an increase in spinal cord injuries in the coming decades (38,52). Unfortunately, the 
health care systems in these regions initially lack the resources to supply newly introduced and patent-
protected interventions, delaying the benefit of hard-earned results for dissemination to all potential 
patients and in turn keeping demographics in these regions similar to what we have seen in, for 
example, Sweden during the last decades. 
Advances in acute management and interventions in SCI will not improve neurological 
function for patients living with chronic SCI. The only hope for improvement of neurological 
function in the chronic state can be found in facilitation of residual function, as has been shown with 
epidural stimulation, or through regeneration, as has been shown in numerous preclinical projects 
and a number of case reports in uncontrolled clinical trials. 
Possibly, the return of meaningful neurological function in severe injuries will require a 
combination of a regeneration strategy and facilitation of function provided by the relatively small 
number of regenerate fibers by epidural spinal cord stimulation. 
Finally, new targets for improving axonal regeneration after trauma constantly emerge from the 
expanding preclinical knowledge of CNS injury biology (226). At present, it is unknown whether the 
regeneration strategy in the ongoing clinical trial described in this thesis will lead to relevant 
functional recovery after chronic SCI in patients. The methods and results described herein should 
however be of relevance in the case of other future attempts at spinal cord regeneration after SCI. 
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CONCLUSIONS 
The papers in this thesis describe parts of the translational process of a preclinical regeneration 
strategy for complete chronic thoracic spinal cord injury to a clinical trial (papers I-III), the short-
term safety reported in the ongoing clinical trial “Safety and Efficacy of SC0806 (Fibroblast Growth 
Factor 1 and a Device) in Traumatic Spinal Cord Injury Subjects” (paper IV), as well as the 
construction of a low-cost light-sheet microscope (paper V). 
 
In conclusion, reaching clinical trial in a translational process is a significant and collaborative 
undertaking requiring co-operation of multiple institutions, multiple professions, multiple funding 
sources and rigorous external control of data quality to ensure safety of study subjects. The papers in 
this thesis details some relevant steps necessary for clinical translation of regeneration strategies in 
chronic SCI. 
 
Specifically, we conclude that: 
 
 
1) Both cranial and caudal demarcation of a thoracic spinal cord injury can be defined 
with electromyography of intercostal muscles (paper I).  
 
2) Using a conversion table between spinal cord neuronal segments and vertebral 
segments, data on human spinal cord size from different published sources could be 
combined in a meta-analysis (paper II).  
 
3) A set of spinal cord injury guiding devices of seven sizes can cover the variability of 
human thoracic spinal cord segments T2–T12 with an acceptable error-of-fit for the 
elliptical shape as well as guiding channels (paper III).  
 
4) From the first six complete (AIS-A) thoracic spinal cord injury subjects operated on 
in the ongoing clinical trial “Safety and Efficacy of SC0806 (Fibroblast Growth Factor 
1 and a Device) in Traumatic Spinal Cord Injury Subjects,” we conclude that with 
precise preoperative and intraoperative neurophysiology, surgery and implantation 
can be performed without negative effects on neurological level and safety and 
tolerability are acceptable to merit the continuation of the study (paper IV).  
 
5) A cost-effective light-sheet microscope could be constructed by modification of an 
outdated microarray-scanner. At this point, limitations on usefulness were primarily 
found in methods for tissue preparation and data analysis (paper V).  
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